AU2002303833A1 - Delivery of opioids through an inhalation route - Google Patents
Delivery of opioids through an inhalation routeInfo
- Publication number
- AU2002303833A1 AU2002303833A1 AU2002303833A AU2002303833A AU2002303833A1 AU 2002303833 A1 AU2002303833 A1 AU 2002303833A1 AU 2002303833 A AU2002303833 A AU 2002303833A AU 2002303833 A AU2002303833 A AU 2002303833A AU 2002303833 A1 AU2002303833 A1 AU 2002303833A1
- Authority
- AU
- Australia
- Prior art keywords
- aerosol
- percent
- particles
- naltrexone
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
DELIVERY OF OPIOIDS THROUGH AN INHALATION ROUTE
CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. provisional application Ser. No.
60/294,203 entitled "Thermal Vapor Delivery of Drugs," filed May 24, 2001, Rabinowitz and Zaffaroni, the entire disclosure of which is hereby incorporated by reference. This application further claims priority to U.S. provisional application Ser. No. 60/317,479 entitled "Aerosol Drug Delivery," filed September 5, 2001, Rabinowitz and Zaffaroni, the entire disclosure of which is hereby incorporated by reference.
FIELD OF THE INVENTION [0002] The present invention relates to the delivery of opioids through an inhalation route. Specifically, it relates to aerosols containing opioids that are used in inhalation therapy.
BACKGROUND OF THE INVENTION [0003] There are a number of currently marketed opioid compositions. The compositions contain at least one active ingredient that provides for observed therapeutic effects. Among the active ingredients given in such opioid compositions are morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, and sufentanil.
[0004] It is desirable to provide a new route of administration for the opioids that rapidly produces peak plasma concentrations of the compounds. The provision of such a route is an object of the present invention.
SUMMARY OF THE INVENTION [0005] The present invention relates to the delivery of opioids through an inhalation route. Specifically, it relates to aerosols containing opioids that are used in inhalation therapy.
[0006] In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an opioid. Preferably, the particles comprise at least 10 percent by weight of an opioid. More preferably, the particles comprise at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent or 99.97 percent by weight of an opioid.
[0007] Typically, the opioid is not morphine or heroin.
[0008] Typically, the aerosol has a mass of at least 1 μg. Preferably, the aerosol has a mass of at least 10 μg. More preferably, the aerosol has a mass of at least 20 μg.
[0009] Typically, the particles comprise less than 10 percent by weight of opioid degradation products. Preferably, the particles comprise less than 5 percent by weight of opioid degradation products. More preferably, the particles comprise less than 2.5, 1, 0.5,
0.1 or 0.03 percent by weight of opioid degradation products.
[0010] Typically, the particles comprise less than 90 percent by weight of water.
Preferably, the particles comprise less than 80 percent by weight of water. More preferably, the particles comprise less than 70 percent, 60 percent, 50 percent, 40 percent,
30 percent, 20 percent, 10 percent, or 5 percent by weight of water.
[0011] Typically, at least 50 percent by weight of the aerosol is amorphous in form, wherein crystalline forms make up less than 50 percent by weight of the total aerosol weight, regardless of the nature of individual particles. Preferably, at least 75 percent by weight of the aerosol is amorphous in form. More preferably, at least 90 percent by weight of the aerosol is amorphous in form.
[0012] Typically, the aerosol has an inhalable aerosol particle density greater than
106 particles/mL. Preferably, the aerosol has an inhalable aerosol particle density greater than 10 particles/mL or 10 particles/mL.
[0013] Typically, the aerosol particles have a mass median aerodynamic diameter of less than 5 microns. Preferably, the particles have a mass median aerodynamic diameter of less than 3 microns. More preferably, the particles have a mass median aerodynamic diameter of less than 2 or 1 micron(s).
[0014] Typically, the aerosol is formed by heating a composition containing an opioid to form a vapor and subsequently allowing the vapor to condense into an aerosol.
[0015] In another composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of morphine, codeine,
naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil. Preferably, the particles comprise at least 10 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil. More preferably, the particles comprise at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent or 99.97 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
[0016] Typically, the aerosol has a mass of at least 1 μg. Preferably, the aerosol has a mass of at least 10 μg. More preferably, the aerosol has a mass of at least 20 μg. [0017] Typically, the particles comprise less than 10 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil degradation products. Preferably, the particles comprise less than 5 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil degradation products. More preferably, the particles comprise less than 2.5, 1, 0.5, 0.1 or 0.03 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil degradation products.
[0018] Typically, the particles comprise less than 90 percent by weight of water.
Preferably, the particles comprise less than 80 percent by weight of water. More preferably, the particles comprise less than 70 percent, 60 percent, 50 percent, 40 percent, 30 percent, 20 percent, 10 percent, or 5 percent by weight of water.
[0019] Typically, at least 50 percent by weight of the aerosol is amorphous in form, wherein crystalline forms make up less than 50 percent by weight of the total aerosol weight, regardless of the nature of individual particles. Preferably, at least 75 percent by weight of the aerosol is amorphous in form. More preferably, at least 90 percent by weight of the aerosol is amorphous in form.
[0020] Typically, where the aerosol comprises morphine, the aerosol has an inhalable aerosol drug mass density of between 5 mg/L and 25 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 7.5 mg/L and 22.5 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 10 mg/L and 20 mg/L.
[0021] Typically, where the aerosol comprises codeine, the aerosol has an inhalable aerosol drug mass density of between 5 mg/L and 25 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 7.5 mg/L and 22.5 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 10 mg/L and 20 mg/L. [0022] Typically, where the aerosol comprises naltrexone, the aerosol has an inhalable aerosol drug mass density of between 15 mg/L and 35 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 17.5 mg/L and 32.5 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 20 mg/L and 30 mg/L.
[0023] Typically, where the aerosol comprises buprenorphine, the aerosol has an inhalable aerosol drug mass density of between 0.1 mg/L and 1 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.15 mg/L and 0.8 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 0.2 mg/L and 0.6 mg/L.
[0024] Typically, where the aerosol comprises fentanyl, the aerosol has an inhalable aerosol drug mass density of between 0.01 mg L and 0.8 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.02 mg/L and 0.6 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 0.3 mg/L and 0.4 mg/L.
[0025] Typically, where the aerosol comprises nalbuphine, the aerosol has an inhalable aerosol drug mass density of between 1 mg/L and 30 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 2 mg/L and 27.5 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 2 mg/L and 25 mg/L.
[0026] Typically, where the aerosol comprises naloxone, the aerosol has an inhalable aerosol drug mass density of between 0.05 mg/L and 3.5 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.1 mg/L and 3 mg/L. More
preferably, the aerosol has an inhalable aerosol drug mass density of between 0.2 mg/L and
2.5 mg/L.
[0027] Typically, where the aerosol comprises butorphanol, the aerosol has an inhalable aerosol drug mass density of between 0.1 mg/L and 3 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.15 mg/L and 2.75 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 0.2 mg/L and 2.5 mg/L.
[0028] Typically, where the aerosol comprises hydromorphone, the aerosol has an inhalable aerosol drug mass density of between 0.1 mg/L and 10 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.2 mg/L and 7.5 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 0.4 mg/L and 5 mg/L.
[0029] Typically, where the aerosol comprises oxycodone, the aerosol has an inhalable aerosol drug mass density of between 0.5 mg/L and 10 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.75 mg/L and 0.8 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 1 mg/L and 0.6 mg/L.
[0030] Typically, where the aerosol comprises meperidine, the aerosol has an inhalable aerosol drug mass density of between 5 mg/L and 100 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 7.5 mg/L and 80 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 10 mg/L and 60 mg/L.
[0031] Typically, where the aerosol comprises methadone, the aerosol has an inhalable aerosol drug mass density of between 0.25 mg/L and 20 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.5 mg/L and 17.5 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 0.75 mg/L and 15 mg/L.
[0032] Typically, where the aerosol comprises pentazocine, the aerosol has an inhalable aerosol drug mass density of between 3 mg/L and 50 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 4 mg/L and 45 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 5 mg/L and
40 mg/L.
[0033] Typically, the aerosol has an inhalable aerosol particle density greater than
106 parti cles/mL. Preferably, the aerosol has an inhalable aerosol particle density greater than 107 particles/mL or 108 particles/mL.
[0034] Typically, the aerosol particles have a mass median aerodynamic diameter of less than 5 microns. Preferably, the particles have a mass median aerodynamic diameter of less than 3 microns. More preferably, the particles have a mass median aerodynamic diameter of less than 2 or 1 micron(s).
[0035] Typically, the aerosol is formed by heating a composition containing morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil to form a vapor and subsequently allowing the vapor to condense into an aerosol.
[0036] In a method aspect of the present invention, an opioid is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an opioid, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. Preferably, the composition comprises at least 10 percent by weight of an opioid. More preferably, the composition comprises at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of an opioid.
[0037] Typically, the opioid is not morphine or heroin.
[0038] Typically, the particles comprise at least 5 percent by weight of an opioid.
Preferably, the particles comprise at least 10 percent by weight of an opioid. More preferably, the particles comprise at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of an opioid.
[0039] Typically, the aerosol has a mass of at least 1 μg. Preferably, the aerosol has a mass of at least 10 μg. More preferably, the aerosol has a mass of at least 20 μg.
[0040] Typically, the particles comprise less than 10 percent by weight of opioid degradation products. Preferably, the particles comprise less than 5 percent by weight of opioid degradation products. More preferably, the particles comprise 2.5, 1, 0.5, 0.1 or
0.03 percent by weight of opioid degradation products.
[0041] Typically, the particles comprise less than 90 percent by weight of water.
Preferably, the particles comprise less than 80 percent by weight of water. More preferably, the particles comprise less than 70 percent, 60 percent, 50 percent, 40 percent,
30 percent, 20 percent, 10 percent, or 5 percent by weight of water.
[0042] Typically, at least 50 percent by weight of the aerosol is amorphous in form, wherein crystalline forms make up less than 50 percent by weight of the total aerosol weight, regardless of the nature of individual particles. Preferably, at least 75 percent by weight of the aerosol is amorphous in form. More preferably, at least 90 percent by weight of the aerosol is amorphous in form.
[0043] Typically, the particles of the delivered condensation aerosol have a mass median aerodynamic diameter of less than 5 microns. Preferably, the particles have a mass median aerodynamic diameter of less than 3 microns. More preferably, the particles have a mass median aerodynamic diameter of less than 2 or 1 micron(s).
[0044] Typically, the delivered aerosol has an inhalable aerosol particle density greater than 106 particles/mL. Preferably, the aerosol has an inhalable aerosol particle density greater than 107 particles/mL or 108 particles/mL.
[0045] Typically, the rate of inhalable aerosol particle formation of the delivered condensation aerosol is greater than 10 particles per second. Preferably, the aerosol is formed at a rate greater than 109 inhalable particles per second. More preferably, the aerosol is formed at a rate greater than 1010 inhalable particles per second.
[0046] Typically, the delivered condensation aerosol is formed at a rate greater than
0.5 mg/second. Preferably, the aerosol is formed at a rate greater than 0.75 mg/second.
More preferably, the aerosol is formed at a rate greater than 1 mg/second, 1.5 mg/second or
2 mg/second.
[0047] Typically, the delivered condensation aerosol results in a peak plasma concentration of an opioid in the mammal in less than 1 h. Preferably, the peak plasma concentration is reached in less than 0.5 h. More preferably, the peak plasma concentration is reached in less than 0.2, 0.1, 0.05, 0.02, 0.01, or 0.005 h (arterial measurement).
[0048] In another method aspect of the present invention, one of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of morphine, codeine,
naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. Preferably, the composition comprises at least 10 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil. More preferably, the composition comprises at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of morphine, codeine, naltrexone, bupreno hine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
[0049] Typically, the particles comprise at least 5 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil. Preferably, the particles comprise at least 10 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil. More preferably, the particles comprise at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent,
99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
[0050] Typically, the aerosol has a mass of at least 1 μg. Preferably, the aerosol has a mass of at least 10 μg. More preferably, the aerosol has a mass of at least 20 μg.
[0051] Typically, the particles comprise less than 10 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil degradation products. Preferably, the particles comprise less than 5 percent by weight of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil degradation products. More preferably, the particles comprise 2.5, 1, 0.5, 0.1 or 0.03 percent by weight of morphine, codeine,
naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil degradation products.
[0052] Typically, the particles comprise less than 90 percent by weight of water.
Preferably, the particles comprise less than 80 percent by weight of water. More preferably, the particles comprise less than 70 percent, 60 percent, 50 percent, 40 percent,
30 percent, 20 percent, 10 percent, or 5 percent by weight of water.
[0053] Typically, at least 50 percent by weight of the aerosol is amorphous in form, wherein crystalline forms make up less than 50 percent by weight of the total aerosol weight, regardless of the nature of individual particles. Preferably, at least 75 percent by weight of the aerosol is amorphous in form. More preferably, at least 90 percent by weight of the aerosol is amorphous in form.
[0054] Typically, the particles of the delivered condensation aerosol have a mass median aerodynamic diameter of less than 5 microns. Preferably, the particles have a mass median aerodynamic diameter of less than 3 microns. More preferably, the particles have a mass median aerodynamic diameter of less than 2 or 1 micron(s).
[0055] Typically, where the aerosol comprises morphine, the delivered aerosol has an inhalable aerosol drug mass density of between 5 mg/L and 25 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 7.5 mg/L and 22.5 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 10 mg/L and 20 mg/L.
[0056] Typically, where the aerosol comprises codeine, the delivered aerosol has an inhalable aerosol drug mass density of between 5 mg/L and 25 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 7.5 mg/L and 22.5 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 10 mg/L and 20 mg/L.
[0057] Typically, where the aerosol comprises naltrexone, the delivered aerosol has an inhalable aerosol drug mass density of between 15 mg/L and 35 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 17.5 mg/L and 32.5 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 20 mg/L and 30 mg/L.
[0058] Typically, where the aerosol comprises buprenorphine, the delivered aerosol has an inhalable aerosol drug mass density of between 0.1 mg/L and 1 mg/L. Preferably,
the aerosol has an inhalable aerosol drug mass density of between 0.15 mg/L and 0.8 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 0.2 mg/L and 0.6 mg/L.
[0059] Typically, where the aerosol comprises fentanyl, the delivered aerosol has an inhalable aerosol drug mass density of between 0.01 mg/L and 0.8 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.02 mg/L and 0.6 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 0.3 mg/L and 0.4 mg/L.
[0060] Typically, where the aerosol comprises nalbuphine, the delivered aerosol has an inhalable aerosol drug mass density of between 1 mg/L and 30 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 2 mg/L and 27.5 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 2 mg/L and 25 mg/L.
[0061] Typically, where the aerosol comprises naloxone, the delivered aerosol has an inhalable aerosol drug mass density of between 0.05 mg/L and 3.5 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.1 mg/L and 3 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 0.2 mg/L and 2.5 mg/L.
[0062] Typically, where the aerosol comprises butorphanol, the delivered aerosol has an inhalable aerosol drug mass density of between 0.1 mg/L and 3 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.15 mg/L and 2.75 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between
0.2 mg/L and 2.5 mg/L.
[0063] Typically, where the aerosol comprises hydromorphone, the delivered aerosol has an inhalable aerosol drag mass density of between 0.1 mg/L and 10 mg/L.
Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.2 mg/L and
7.5 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 0.4 mg/L and 5 mg/L.
[0064] Typically, where the aerosol comprises oxycodone, the delivered aerosol has an inhalable aerosol drug mass density of between 0.5 mg/L and 10 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.75 mg/L and 0.8 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 1 mg/L and 0.6 mg/L.
[0065] Typically, where the aerosol comprises meperidine, the delivered aerosol has an inhalable aerosol drug mass density of between 5 mg/L and 100 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 7.5 mg/L and 80 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 10 mg/L and 60 mg/L.
[0066] Typically, where the aerosol comprises methadone, the delivered aerosol has an inhalable aerosol drug mass density of between 0.25 mg/L and 20 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.5 mg/L and 17.5 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 0.75 mg/L and 15 mg/L.
[0067] Typically, where the aerosol comprises pentazocine, the delivered aerosol has an inhalable aerosol drug mass density of between 3 mg/L and 50 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 4 mg/L and 45 mg/L.
More preferably, the aerosol has an inhalable aerosol drug mass density of between 5 mg/L and 40 mg/L.
[0068] Typically, the delivered aerosol has an inhalable aerosol particle density greater than 106 particles/mL. Preferably, the aerosol has an inhalable aerosol particle density greater than 107 particles/mL or 108 particles/mL.
[0069] Typically, the rate of inhalable aerosol particle formation of the delivered condensation aerosol is greater than 108 particles per second. Preferably, the aerosol is formed at a rate greater than 109 inhalable particles per second. More preferably, the aerosol is formed at a rate greater than 1010 inhalable particles per second.
[0070] Typically, the delivered condensation aerosol is formed at a rate greater than
0.5 mg/second. Preferably, the aerosol is formed at a rate greater than 0.75 mg/second.
More preferably, the aerosol is formed at a rate greater than 1 mg/second, 1.5 mg/second or
2 mg/second.
[0071] Typically, where the condensation aerosol comprises morphine, between 5 mg and 25 mg of morphine are delivered to the mammal in a single inspiration. Preferably, between 7.5 mg and 22.5 mg of morphine are delivered to the mammal in a single inspiration. More preferably, between 10 mg and 20 mg of morphine are delivered in a single inspiration.
[0072] Typically, where the condensation aerosol comprises codeine, between 5 mg and 25 mg of codeine are delivered to the mammal in a single inspiration. Preferably,
between 7.5 mg and 22.5 mg of codeine are delivered to the mammal in a single inspiration. More preferably, between 10 mg and 20 mg of codeine are delivered in a single inspiration.
[0073] Typically, where the condensation aerosol comprises naltrexone, between 15 mg and 35 mg of naltrexone are delivered to the mammal in a single inspiration.
Preferably, between 17.5 mg and 32.5 mg of naltrexone are delivered to the mammal in a single inspiration. More preferably, between 20 mg and 30 mg of naltrexone are delivered in a single inspiration.
[0074] Typically, where the condensation aerosol comprises buprenorphine, between 0.1 mg and 1 mg of buprenorphine are delivered to the mammal in a single inspiration. Preferably, between 0.15 mg and 0.8 mg of buprenorphine are delivered to the mammal in a single inspiration. More preferably, between 0.2 mg and 0.6 mg of naltrexone are delivered in a single inspiration.
[0075] Typically, where the condensation aerosol comprises fentanyl, between 0.01 mg and 0.8 mg of fentanyl are delivered to the mammal in a single inspiration. Preferably, between 0.02 mg and 0.6 mg of fentanyl are delivered to the mammal in a single inspiration. More preferably, between 0.03 mg and 0.4 mg of fentanyl are delivered in a single inspiration.
[0076] Typically, where the condensation aerosol comprises nalbuphine, between 1 mg and 30 mg of nalbuphine are delivered to the mammal in a single inspiration.
Preferably, between 2 mg and 27.5 mg of nalbuphine are delivered to the mammal in a single inspiration. More preferably, between 3 mg and 25 mg of nalbuphine are delivered in a single inspiration.
[0077] Typically, where the condensation aerosol comprises naloxone, between
0.05 mg and 3.5 mg of naloxone are delivered to the mammal in a single inspiration.
Preferably, between 0.1 mg and 3 mg of naloxone are delivered to the mammal in a single inspiration. More preferably, between 0.2 mg and 2.5 mg of naloxone are delivered in a single inspiration.
[0078] Typically, where the condensation aerosol comprises butorphanol, between
0.1 mg and 3 mg of butorphanol are delivered to the mammal in a single inspiration.
Preferably, between 0.15 mg and 2.75 mg of butorphanol are delivered to the mammal in a single inspiration. More preferably, between 0.2 mg and 2.5 mg of butorphanol are delivered in a single inspiration.
[0079] Typically, where the condensation aerosol comprises hydromorphone, between 0.1 mg and 10 mg of hydromorphone are delivered to the mammal in a single inspiration. Preferably, between 0.2 mg and 7.5 mg of hydromorphone are delivered to the mammal in a single inspiration. More preferably, between 0.4 mg and 5 mg of hydromorphone are delivered in a single inspiration.
[0080] Typically, where the condensation aerosol comprises oxycodone, between
0.5 mg and 10 mg of oxycodone are delivered to the mammal in a single inspiration.
Preferably, between 0.75 mg and 8 mg of oxycodone are delivered to the mammal in a single inspiration. More preferably, between 1 mg and 6 mg of oxycodonel are delivered in a single inspiration.
[0081] Typically, where the condensation aerosol comprises meperidine, between 5 mg and 100 mg of meperidine are delivered to the mammal in a single inspiration.
Preferably, between 7.5 mg and 80 mg of meperidine are delivered to the mammal in a single inspiration. More preferably, between 10 mg and 60 mg of meperidine are delivered in a single inspiration.
[0082] Typically, where the condensation aerosol comprises methadone, between
0.25 mg and 20 mg of methadone are delivered to the mammal in a single inspiration.
Preferably, between 0.5 mg and 17.5 mg of methadone are delivered to the mammal in a single inspiration. More preferably, between 0.75 mg and 15 mg of methadone are delivered in a single inspiration.
[0083] Typically, where the condensation aerosol comprises pentazocine, between
3 mg and 50 mg of pentazocine are delivered to the mammal in a single inspiration.
Preferably, between 4 mg and 45 mg of pentazocine are delivered to the mammal in a single inspiration. More preferably, between 5 mg and 40 mg of pentazocine are delivered in a single inspiration.
[0084] Typically, the delivered condensation aerosol results in a peak plasma concentration of morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil in the mammal in less than 1 h. Preferably, the peak plasma concentration is reached in less than 0.5 h. More preferably, the peak plasma concentration is reached in less than 0.2, 0.1, 0.05, 0.02, 0.01, or 0.005 h (arterial measurement).
[0085] In a kit aspect of the present invention, a kit for delivering an opioid through an inhalation route to a mammal is provided which comprises: a) a composition
comprising at least 5 percent by weight of an opioid; and, b) a device that forms an opioid aerosol from the composition, for inhalation by the mammal. Preferably, the composition comprises at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of an opioid.
[0086] Typically, the device contained in the kit comprises: a) an element for heating the opioid composition to form a vapor; b) an element allowing the vapor to cool to form an aerosol; and, c) an element permitting the mammal to inhale the aerosol. [0087] In another kit aspect of the present invention, a kit for delivering morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of morphine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butorphanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil; and, b) a device that forms a moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil aerosol from the composition, for inhalation by the mammal. Preferably, the composition comprises at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil. [0088] Typically, the device contained in the kit comprises: a) an element for heating the moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil composition to form a vapor; b) an element allowing the vapor to cool to form an aerosol; and, c) an element permitting the mammal to inhale the aerosol.
BRIEF DESCRIPTION OF THE FIGURE [0089] Fig. 1 shows a cross-sectional view of a device used to deliver opioid aerosols to a mammal through an inhalation route.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0090] "Aerodynamic diameter" of a given particle refers to the diameter of a spherical droplet with a density of 1 g/mL (the density of water) that has the same settling velocity as the given particle.
[0091] "Aerosol" refers to a suspension of solid or liquid particles in a gas.
[0092] "Aerosol drug mass density" refers to the mass of opioid per unit volume of aerosol.
[0093] "Aerosol mass density" refers to the mass of particulate matter per unit volume of aerosol.
[0094] "Aerosol particle density" refers to the number of particles per unit volume of aerosol.
[0095] "Amoφhous particle" refers to a particle that does not contain more than 50 percent by weight of a crystalline form. Preferably, the particle does not contain more than
25 percent by weight of a crystalline form. More preferably, the particle does not contain more than 10 percent by weight of a crystalline form.
[0096] "Buprenoφhine" refers to 17-(cyclopropylmethyl)-α-( 1 , 1 -dimethylethyl)-
4,5-epoxy- 18,19-dihydro-3 -hydroxy-6-methoxy-α-methyl-6, 14-ethanomoφhinan-7- methanol.
[0097] "Buprenoφhine degradation product" refers to a compound resulting from a chemical modification of buprenoφhine. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0098] "Butoφhanol" refers to 17-(cyclobutylmethyl)moφhinan-3 , 14-diol.
[0099] "Butoφhanol degradation product" refers to a compound resulting from a chemical modification of butoφhanol. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis. An example of a degradation product is a compound of molecular formula C5H8O.
[0100] "Codeine" refers to 7,8-didehydro-4,5-epoxy-3-methoxy-l 7- methylmoφhinan-6-ol.
[0101] "Codeine degradation product" refers to a compound resulting from a chemical modification of codeine. The modification, for example, can be the result of a
thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0102] "Condensation aerosol" refers to an aerosol formed by vaporization of a substance followed by condensation of the substance into an aerosol.
[0103] "Fentanyl" refers to N-phenyl-N-[l -(2-phenylethyl)-4- piperidinyl]propanamide.
[0104] "Fentanyl degradation product" refers to a compound resulting from a chemical modification of fentanyl. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0105] "Hydromoφhone" refers to 4,5-epoxy-3-hydroxy-17-methylmoφhinan-6- one.
[0106] "Hydromoφhone degradation product" refers to a compound resulting from a chemical modification of hydromoφhone. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0107] "Inhalable aerosol drug mass density" refers to the aerosol drug mass density produced by an inhalation device and delivered into a typical patient tidal volume.
[0108] "Inhalable aerosol mass density" refers to the aerosol mass density produced by an inhalation device and delivered into a typical patient tidal volume.
[0109] "Inhalable aerosol particle density" refers to the aerosol particle density of particles of size between 100 rim and 5 microns produced by an inhalation device and delivered into a typical patient tidal volume.
[0110] "Mass median aerodynamic diameter" or "MMAD" of an aerosol refers to the aerodynamic diameter for which half the particulate mass of the aerosol is contributed by particles with an aerodynamic diameter larger than the MMAD and half by particles with an aerodynamic diameter smaller than the MMAD.
[0111] "Meperidine" refers to l-methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester.
[0112] "Meperidine degradation product" refers to a compound resulting from a chemical modification of meperidine. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0113] "Methadone" refers to 6-dimethylamino-4,4-diphenyl-3-heptanone.
[0114] "Methadone degradation product" refers to a compound resulting from a chemical modification of methadone. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0115] "Moφhine" refers to 7,8-didehydro-4,5-epoxy-17-methylmoφhinan-3,6- diol.
[0116] "Moφhine degradation product" refers to a compound resulting from a chemical modification of moφhine. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0117] "Nalbuphine" refers to 17-(cyclobutylmethyl)-4,5-epoxy-moφhinan-3,6, 14- triol.
[0118] "Nalbuphine degradation product" refers to a compound resulting from a chemical modification of nalbuphine. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0119] "Naloxone" refers to 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)moφhinan-
6-one.
[0120] "Naloxone degradation product" refers to a compound resulting from a chemical modification of naloxone. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0121] "Naltrexone" refers to 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy- moφhinan-6-one.
[0122] "Naltrexone degradation product" refers to a compound resulting from a chemical modification of naltrexone. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0123] "Opioid degradation product" refers to a compound resulting from a chemical modification of an opioid. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0124] "Oxycodone" refers to 4,5-epoxy-14-hydroxy-3-methoxy-17- methylmoφhin.m-6-one.
[0125] "Oxycodone degradation product" refers to a compound resulting from a chemical modification of oxycodone. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0126] "Pentazocine" refers to l,2,3,4,5,6-hexahydro-6,l l-dimethyl-3-(3-methyl-2- butenyl)-2,6-methano-3-benzazocin-8-ol.
[0127] "Pentazocine degradation product" refers to a compound resulting from a chemical modification of pentazocine. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0128] "Rate of aerosol formation" refers to the mass of aerosolized particulate matter produced by an inhalation device per unit time.
[0129] "Rate of inhalable aerosol particle formation" refers to the number of particles of size between 100 nm and 5 microns produced by an inhalation device per unit time.
[0130] "Rate of drug aerosol formation" refers to the mass of aerosolized opioid produced by an inhalation device per unit time.
[0131] "Remifentanil" refers to 3-[4-methoxycarbonyl-4-[(l- oxopropyl)phenylamino]-l-piperidine]propanoic acid methyl ester.
[0132] "Remifentanil degradation product" refers to a compound resulting from a chemical modification of remifentanil. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0133] "Settling velocity" refers to the terminal velocity of an aerosol particle undergoing gravitational settling in air.
[0134] "Typical patient tidal volume" refers to 1 L for an adult patient and 15 mL/kg for a pediatric patient.
[0135] "Vapor" refers to a gas, and "vapor phase" refers to a gas phase. The term
"thermal vapor" refers to a vapor phase, aerosol, or mixture of aerosol-vapor phases, formed preferably by heating.
Formation of Opioid Containing Aerosols
[0136] Any suitable method is used to form the aerosols of the present invention. A preferred method, however, involves heating a composition comprising an opioid to form a vapor, followed by cooling of the vapor such that it condenses to provide an opioid comprising aerosol (condensation aerosol). The composition is heated in one of four forms: as pure active compound (e.g., pure moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil); as a mixture of active compound and a pharmaceutically acceptable excipient; as a salt form of the pure active compound; and, as a mixture of active compound salt form and a pharmaceutically acceptable excipient.
[0137] Salt forms of opioids (e.g., moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil) are either commercially available or are obtained from the corresponding free base using well known methods in the art. A variety of pharmaceutically acceptable salts are suitable for aerosolization. Such salts include, without limitation, the following: hydrochloric acid, hydrobromic acid, acetic acid, maleic acid, formic acid, and fumaric acid salts.
[0138] Pharmaceutically acceptable excipients may be volatile or nonvolatile.
Volatile excipients, when heated, are concurrently volatilized, aerosolized and inhaled with the opioid. Classes of such excipients are known in the art and include, without limitation, gaseous, supercritical fluid, liquid and solid solvents. The following is a list of exemplary carriers within the classes: water; teφenes, such as menthol; alcohols, such as ethanol, propylene glycol, glycerol and other similar alcohols; dimethylformamide; dimethylacetamide; wax; supercritical carbon dioxide; dry ice; and mixtures thereof.
[0139] Solid supports on which the composition is heated are of a variety of shapes.
Examples of such shapes include, without limitation, cylinders of less than 1.0 mm in diameter, boxes of less than 1.0 mm thickness and virtually any shape permeated by small
(e.g., less than 1.0 mm-sized) pores. Preferably, solid supports provide a large surface to volume ratio (e.g., greater than 100 per meter) and a large surface to mass ratio (e.g., greater than 1 cm2 per gram).
[0140] A solid support of one shape can also be transformed into another shape with different properties. For example, a flat sheet of 0.25 mm thickness has a surface to volume ratio of approximately 8,000 per meter. Rolling the sheet into a hollow cylinder of
1 cm diameter produces a support that retains the high surface to mass ratio of the original sheet but has a lower surface to volume ratio (about 400 per meter). [0141] A number of different materials are used to construct the solid supports.
Classes of such materials include, without limitation, metals, inorganic materials, carbonaceous materials and polymers. The following are examples of the material classes: aluminum, silver, gold, stainless steel, copper and tungsten; silica, glass, silicon and alumina; graphite, porous carbons, carbon yarns and carbon felts; polytetrafluoroethylene and polyethylene glycol. Combinations of materials and coated variants of materials are used as well.
[0142] Where aluminum is used as a solid support, aluminum foil is a suitable material. Examples of silica, alumina and silicon based materials include amphorous silica S-5631 (Sigma, St. Louis, MO), BCR171 (an alumina of defined surface area greater than 2 m2/g from Aldrich, St. Louis, MO) and a silicon wafer as used in the semiconductor industry. Carbon yarns and felts are available from American Kynol, Inc., New York, NY. Chromatography resins such as octadecycl silane chemically bonded to porous silica are exemplary coated variants of silica.
[0143] The heating of the opioid compositions is performed using any suitable method. Examples of methods by which heat can be generated include the following: passage of current through an electrical resistance element; absoφtion of electromagnetic radiation, such as microwave or laser light; and, exothermic chemical reactions, such as exothermic solvation, hydration of pyrophoric materials and oxidation of combustible materials.
Delivery of Opioid Containing Aerosols
[0144] Opioid containing aerosols of the present invention are delivered to a mammal using an inhalation device. Where the aerosol is a condensation aerosol, the device has at least three elements: an element for heating an opioid containing composition to form a vapor; an element allowing the vapor to cool, thereby providing a condensation aerosol; and, an element permitting the mammal to inhale the aerosol. Various suitable heating methods are described above. The element that allows cooling is, in it simplest form, an inert passageway linking the heating means to the inhalation means. The element permitting inhalation is an aerosol exit portal that forms a connection between the cooling element and the mammal's respiratory system.
[0145] One device used to deliver the opioid containing aerosol is described in reference to Fig. 1. Delivery device 100 has a proximal end 102 and a distal end 104, a heating module 106, a power source 108, and a mouthpiece 110. An opioid composition is deposited on a surface 112 of heating module 106. Upon activation of a user activated switch 114, power source 108 initiates heating of heating module 106 (e.g, through ignition of combustible fuel or passage of current through a resistive heating element). The opioid composition volatilizes due to the heating of heating module 106 and condenses to form a condensation aerosol prior to reaching the mouthpiece 110 at the proximal end of the device 102. Air flow traveling from the device distal end 104 to the mouthpiece 110 carries the condensation aerosol to the mouthpiece 110, where it is inhaled by the mammal. [0146] Devices, if desired, contain a variety of components to facilitate the delivery of opioid containing aerosols. For instance, the device may include any component known in the art to control the timing of drug aerosolization relative to inhalation (e.g., breath- actuation), to provide feedback to patients on the rate and/or volume of inhalation, to prevent excessive use (i.e., "lock-out" feature), to prevent use by unauthorized individuals, and/or to record dosing histories.
Dosage of Opioid Containing Aerosols
[0147] The dosage amount of an opiod in aerosol form is generally no greater than twice the standard dose of the drug given orally. For instance, moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, and pentazocine, are given at strengths of 15 mg, 15 mg, 25 mg, 0.3 to 0.6 mg, 0.1 to 0.4 mg, 10 mg, 0.4 to 2 mg, 0.5 to 2 mg, 2 to 4 mg, 5 mg,
50 mg, 2.5 to 10 mg, and 30 mg, respectively for the treatment of pain, alcohol addiction and maintenance of opioid addicts. As aerosols, 5 mg to 25 mg of moφhine, 5 mg to 25 mg of codeine, 15 mg to 35 mg of naltrexone, 0.1 to 1 mg of buprenoφhine, 0.01 to 0.8 mg of fentanyl, 1 to 30 mg of nalbuphine, 0.05 to 3.5 mg of naloxone, 0.1 to 3 mg of butoφhanol, 0.1 to 10 mg of hydromoφhone, 0.5 to 10 mg of oxycodone, 5 to 100 mg of meperidine, 0.25 to 20 mg of methadone, and 3 to50 mg of pentazocine are generally provided for the same indications. A typical dosage of an opioid aerosol is either administered as a single inhalation or as a series of inhalations taken within an hour or less
(dosage equals sum of inhaled amounts). Where the drug is administered as a series of inhalations, a different amount may be delivered in each inhalation.
[0148] One can determine the appropriate dose of opioid containing aerosols to treat a particular condition using methods such as animal experiments and a dose-finding (Phase I/II) clinical trial. One animal experiment involves measuring plasma concentrations of drug in an animal after its exposure to the aerosol. Mammals such as dogs or primates are typically used in such studies, since their respiratory systems are similar to that of a human. Initial dose levels for testing in humans is generally less than or equal to the dose in the mammal model that resulted in plasma drag levels associated with a therapeutic effect in humans. Dose escalation in humans is then performed, until either an optimal therapeutic response is obtained or a dose-limiting toxicity is encountered.
Analysis of Opioid Containing Aerosols
[0149] Purity of an opioid containing aerosol is determined using a number of methods, examples of which are described in Sekine et al, Journal of Forensic Science 32:1271-1280 (1987) and Martin et al, Journal of Analytic Toxicology 13:158-162 (1989). One method involves forming the aerosol in a device through which a gas flow (e.g., air flow) is maintained, generally at a rate between 0.4 and 60 L/min. The gas flow carries the aerosol into one or more traps. After isolation from the trap, the aerosol is subjected to an analytical technique, such as gas or liquid chromatography, that permits a determination of composition purity.
[0150] A variety of different traps are used for aerosol collection. The following list contains examples of such traps: filters; glass wool; impingers; solvent traps, such as dry ice-cooled ethanol, methanol, acetone and dichloromethane traps at various pH values; syringes that sample the aerosol; empty, low-pressure (e.g., vacuum) containers into which the aerosol is drawn; and, empty containers that fully surround and enclose the aerosol generating device. Where a solid such as glass wool is used, it is typically extracted with a solvent such as ethanol. The solvent extract is subjected to analysis rather than the solid (i.e., glass wool) itself. Where a syringe or container is used, the container is similarly extracted with a solvent.
[0151] The gas or liquid chromatograph discussed above contains a detection system (i.e., detector). Such detection systems are well known in the art and include, for example, flame ionization, photon absoφtion and mass spectrometry detectors. An advantage of a mass spectrometry detector is that it can be used to determine the structure of opioid degradation products.
[0152] Particle size distribution of an opioid containing aerosol is determined using any suitable method in the art (e.g. , cascade impaction). An Andersen Eight Stage Non- viable Cascade Impactor (Andersen Instruments, Smyrna, GA) linked to a furnace tube by a mock throat (USP throat, Andersen Instruments, Smyrna, GA) is one system used for cascade impaction studies.
[0153] Inhalable aerosol mass density is determined, for example, by delivering a drag-containing aerosol into a confined chamber via an inhalation device and measuring the mass collected in the chamber. Typically, the aerosol is drawn into the chamber by having a pressure gradient between the device and the chamber, wherein the chamber is at lower pressure than the device. The volume of the chamber should approximate the tidal volume of an inhaling patient.
[0154] Inhalable aerosol drug mass density is determined, for example, by delivering a drug-containing aerosol into a confined chamber via an inhalation device and measuring the amount of active drug compound collected in the chamber. Typically, the aerosol is drawn into the chamber by having a pressure gradient between the device and the chamber, wherein the chamber is at lower pressure than the device. The volume of the chamber should approximate the tidal volume of an inhaling patient. The amount of active drug compound collected in the chamber is determined by extracting the chamber, conducting chromatographic analysis of the extract and comparing the results of the chromatographic analysis to those of a standard containing known amounts of drug. [0155] Inhalable aerosol particle density is determined, for example, by delivering aerosol phase drug into a confined chamber via an inhalation device and measuring the number of particles of given size collected in the chamber. The number of particles of a given size may be directly measured based on the light-scattering properties of the particles. Alternatively, the number of particles of a given size is determined by measuring the mass of particles within the given size range and calculating the number of particles based on the mass as follows: Total number of particles = Sum (from size range 1 to size range N) of number of particles in each size range. Number of particles in a given size range = Mass in the size range/Mass of a typical particle in the size range. Mass of a typical particle in a given size range = π*D3*φ/6, where D is a typical particle diameter in the size range (generally, the mean boundary MMADs defining the size range) in microns, φ is the particle density (in g/mL) and mass is given in units of picograms (g"12).
[0156] Rate of inhalable aerosol particle formation is determined, for example, by delivering aerosol phase drag into a confined chamber via an inhalation device. The delivery is for a set period of time (e.g., 3 s), and the number of particles of a given size collected in the chamber is determined as outlined above. The rate of particle formation is equal to the number of 100 nm to 5 micron particles collected divided by the duration of the collection time.
[0157] Rate of aerosol formation is determined, for example, by delivering aerosol phase drug into a confined chamber via an inhalation device. The delivery is for a set period of time (e.g., 3 s), and the mass of particulate matter collected is determined by weighing the confined chamber before and after the delivery of the particulate matter. The rate of aerosol formation is equal to the increase in mass in the chamber divided by the duration of the collection time. Alternatively, where a change in mass of the delivery device or component thereof can only occur through release of the aerosol phase particulate matter, the mass of particulate matter may be equated with the mass lost from the device or component during the delivery of the aerosol. In this case, the rate of aerosol formation is equal to the decrease in mass of the device or component during the delivery event divided by the duration of the delivery event.
[0158] Rate of drag aerosol formation is determined, for example, by delivering an opioid containing aerosol into a confined chamber via an inhalation device over a set period of time (e.g., 3 s). Where the aerosol is pure opioid, the amount of drug collected in the chamber is measured as described above. The rate of drag aerosol formation is equal to the amount of opioid collected in the chamber divided by the duration of the collection time. Where the opioid containing aerosol comprises a pharmaceutically acceptable excipient, multiplying the rate of aerosol formation by the percentage of opioid in the aerosol provides the rate of drug aerosol formation.
Utility of Opioid Containing Aerosols
[0159] The moφhine, codeine, fentanyl, nalbuphine, butoφhanol, hydromoφhone, oxycodone, meperidine, pentazocine, remifentanil, or sufentanil containing aerosols of the present invention are typically used to treat pain. Naltrexone and naloxone are typically used to treat alcohol abuse and to provide opioid reversal. Buprenoφhine and methadone are typically used in the maintenance of opioid addicts. Other opioids are generally provided for the types of indications listed above.
[0160] The following examples are meant to illustrate, rather than limit, the present invention.
[0161] Moφhine sulfate, codeine, naltrexone hydrochloride, buprenoφhine hydrochloride, fentanyl citrate, nalbuphine hydrochloride, naloxone hydrochloride, butoφhanol tartrate, hydromoφhone hydrochloride, oxycodone hydrochloride, meperidine hydrochloride, methadone hydrochloride, and pentazocine are commercially available from Sigma (www.sigma-aldrich.com). Other opioids can be obtained from commercial sources or synthesized using standard methods in the art.
EXAMPLE 1
General Procedure for Obtaining Free Base of a Compound Salt
[0162] Approximately 1 g of salt (e.g., mono hydrochloride) is dissolved in deionized water (-30 mL). Three equivalents of sodium hydroxide (I N NaOHaq) is added dropwise to the solution, and the pH is checked to ensure it is basic. The aqueous solution is extracted four times with dichloromethane (~50 mL), and the extracts are combined, dried (Na2SO ) and filtered. The filtered organic solution is concentrated using a rotary evaporator to provide the desired free base. If necessary, purification of the free base is performed using standard methods such as chromatography or recrystallization.
EXAMPLE 2
General Procedure for Volatilizing Compounds from Halogen Bulb
[0163] A solution of drag in approximatelyl20 μL dichloromethane is coated on a
3.5 cm x 7.5 cm piece of aluminum foil (precleaned with acetone). The dichloromethane is allowed to evaporate. The coated foil is wrapped around a 300 watt halogen tube (Feit Electric Company, Pico Rivera, CA), which is inserted into a glass tube sealed at one end with a rubber stopper. Running 90 V of alternating current (driven by line power controlled by a variac) through the bulb for 3.5-5 s affords thermal vapor (including aerosol), which is collected on the glass tube walls. Reverse-phase HPLC analysis with detection by absoφtion of 225 nm light is used to determine the purity of the aerosol.
(When desired, the system is flushed through with argon prior to volatilization.) To obtain higher purity aerosols, one can coat a lesser amount of drag, yielding a thinner film to heat. A linear decrease in film thickness is associated with a linear decrease in impurities. [0164] The following aerosols were obtained using this procedure: moφhine (3.1 mg, 100% purity); codeine (1.01 mg, 100% purity); naltrexone (1 mg, 97.4% purity); buprenorphine (1.1 mg, 98.7% purity); fentanyl (0.13 mg, 100% purity); nalbuphine (0.4 mg, 100%> purity); naloxone (1.07 mg, 99.24%) purity); and, butoφhanol (1.38 mg, 97.2% purity).
EXAMPLE 3
Particle Size, Particle Density, and Rate of InhalableP article Formation of Buprenorphine
Aerosol
[0165] A solution of 1.5 mg buprenoφhine in 100 μL 50/50 mixture of dichloromethane and methyl ethyl ketone was spread out in a thin layer on the central portion of a 3.5 cm x 7 cm sheet of aluminum foil. The dichloromethane and methyl ethyl ketone mixture were allowed to evaporate. The aluminum foil was wrapped around a 300 watt halogen tube, which was inserted into a T-shaped glass tube. Both of the openings of the tube were left open and the third opening was connected to a 1 liter, 3 -neck glass flask. The glass flask was further connected to a large piston capable of drawing 1.1 liters of air through the flask. Alternating current was run through the halogen bulb by application of 90 V using a variac connected to 110 V line power. Within 1 s, an aerosol appeared and was drawn into the 1 L flask by use of the piston, with collection of the aerosol terminated after 6 s. The aerosol was analyzed by connecting the 1 L flask to an eight-stage Andersen non- viable cascade impactor. Results are shown in table 1. MMAD of the collected aerosol was 1.1 microns with a geometric standard deviation of 4.2. Also shown in table 1 is the number of particles collected on the various stages of the cascade impactor, given by the mass collected on the stage divided by the mass of a typical particle trapped on that stage. The mass of a single particle of diameter D is given by the volume of the particle, πD3/6, multiplied by the density of the drug (taken to be 1 g/cm3). The inhalable aerosol particle density is the sum of the numbers of particles collected on impactor stages 3 to 8 divided by the collection volume of 1 L, giving an inhalable aerosol particle density of 7.2 x 107particles/mL. The rate of inhalable aerosol particle formation is the sum of the
numbers of particles collected on impactor stages 3 through 8 divided by the formation time of 6 s, giving a rate of inhalable aerosol particle formation of 1.2 x 1010 particles/second.
Table 1 : Determination of the characteristics of a buprenoφhine condensation aerosol by cascade impaction using an Andersen 8-stage non- viable cascade impactor run at 1 cubic foot per minute air flow.
EXAMPLE 4
Drug Mass Density and Rate of Drug Aerosol Formation of Buprenorphine Aerosol
[0166] A solution of 1.2 mg buprenoφhine in 100 μL 50/50 mixture of dichloromethane and methyl ethyl ketone was spread out in a thin layer on the central portion of a 3.5 cm x 7 cm sheet of aluminum foil. The dichloromethane and methyl ethyl ketone were allowed to evaporate. The aluminum foil was wrapped around a 300 watt halogen tube, which was inserted into a T-shaped glass tube. Both of the openings of the tube were left open and the third opening was connected to a 1 liter, 3 -neck glass flask. The glass flask was further connected to a large piston capable of drawing 1.1 liters of air through the flask. Alternating current was run through the halogen bulb by application of 90 V using a variac connected to 110 V line power. Within seconds, an aerosol appeared and was drawn into the 1 L flask by use of the piston, with formation of the aerosol terminated after 6 s. The aerosol was allowed to sediment onto the walls of the 1 L flask for approximately 30 minutes. The flask was then extracted with acetonitrile and the extract analyzed by HPLC with detection by light absoφtion at 225 nm. Comparison with
standards containing known amounts of buprenoφhine revealed that 0.2 mg of > 99%) pure buprenoφhine had been collected in the flask, resulting in an aerosol drag mass density of 0.2 mg/L. The aluminum foil upon which the buprenoφhine had previously been coated was weighed following the experiment. Of the 1.2 mg originally coated on the aluminum, 0.7 mg of the material was found to have aerosolized in the 6 s time period, implying a rate of drug aerosol formation of 0.1 mg/s.
Claims (15)
1. An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an opioid, and wherein the opioid is not moφhine or heroin.
2. An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
3. The aerosol according to Claim 2, wherein the aerosol particles have a mass median aerodynamic diameter of less than 3 microns.
4. The aerosol according to Claim 2, wherein the particles comprise less than 5 percent by weight of moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil degradation products.
5. The aerosol according to Claim 2, wherein the aerosol comprises particles comprising at least 90 percent by weight of moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
6. The aerosol according to Claim 5, wherein the aerosol particles have a mass median aerodynamic diameter less than 2 microns.
7. The aerosol according to Claim 6, wherein the aerosol comprises particles comprising at least 95 percent by weight of moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
8. A method of delivering moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil to a mammal through an inhalation route, wherein the route comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.
9. The method according to Claim 8, wherein the particles comprise at least 10 percent by weight of moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
10. The method according to Claim 8, wherein the aerosol particles have a mass median aerodynamic diameter of less than 3 microns.
11. The method according to Claim 8, wherein the particles comprise less than 5 percent by weight of moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil degradation products.
12. The method according to Claim 10, wherein the aerosol comprises particles comprising at least 90 percent by weight of moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
13. The method according to Claim 12, wherein the aerosol particles have a mass median aerodynamic diameter less than 2 microns.
14. The method according to Claim 13, wherein the aerosol comprises particles comprising at least 95 percent by weight of moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromorphone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil.
15. A kit for delivering moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil through an inhalation route to a mammal, wherein the kit comprises: a) a composition comprising at least 5 percent by weight of moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil; and, b) a device that forms a moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil aerosol from the composition, for inhalation by the mammal
.and wherein the device comprises: a) an element for heating the moφhine, codeine, naltrexone, buprenoφhine, fentanyl, nalbuphine, naloxone, butoφhanol, hydromoφhone, oxycodone, meperidine, methadone, pentazocine, remifentanil, or sufentanil composition to form a vapor; b) an element allowing the vapor to cool to form an aerosol; and, c) an element permitting the mammal to inhale the aerosol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008200911A AU2008200911B2 (en) | 2001-05-24 | 2008-02-27 | Delivery of opioids through an inhalation route |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29420301P | 2001-05-24 | 2001-05-24 | |
US60/294,203 | 2001-05-24 | ||
US31747901P | 2001-09-05 | 2001-09-05 | |
US60/317,479 | 2001-09-05 | ||
PCT/US2002/016099 WO2002094234A1 (en) | 2001-05-24 | 2002-05-21 | Delivery of opioids through an inhalation route |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2008200911A Division AU2008200911B2 (en) | 2001-05-24 | 2008-02-27 | Delivery of opioids through an inhalation route |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002303833A1 true AU2002303833A1 (en) | 2003-05-08 |
AU2002303833B2 AU2002303833B2 (en) | 2007-11-29 |
Family
ID=30772632
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002314784A Abandoned AU2002314784A1 (en) | 2001-05-24 | 2002-05-15 | Delivery of stimulants through an inhalation route |
AU2002310015A Expired AU2002310015B2 (en) | 2001-05-24 | 2002-05-20 | Delivery of antipsychotics through an inhalation route |
AU2002303833A Ceased AU2002303833B2 (en) | 2001-05-24 | 2002-05-21 | Delivery of opioids through an inhalation route |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002314784A Abandoned AU2002314784A1 (en) | 2001-05-24 | 2002-05-15 | Delivery of stimulants through an inhalation route |
AU2002310015A Expired AU2002310015B2 (en) | 2001-05-24 | 2002-05-20 | Delivery of antipsychotics through an inhalation route |
Country Status (16)
Country | Link |
---|---|
US (75) | US6737042B2 (en) |
EP (14) | EP1392262A1 (en) |
JP (7) | JP2005503425A (en) |
AT (11) | ATE401064T1 (en) |
AU (3) | AU2002314784A1 (en) |
BE (1) | BE2013C054I2 (en) |
CA (7) | CA2446904A1 (en) |
DE (4) | DE60235851D1 (en) |
DK (1) | DK1389098T3 (en) |
ES (5) | ES2312571T3 (en) |
FR (1) | FR13C0051I1 (en) |
MX (2) | MXPA03010703A (en) |
NZ (6) | NZ529422A (en) |
PL (3) | PL363996A1 (en) |
PT (2) | PT1389098E (en) |
WO (1) | WO2002094236A1 (en) |
Families Citing this family (371)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030203036A1 (en) * | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
US7632517B2 (en) * | 1997-10-01 | 2009-12-15 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
US7087215B2 (en) * | 1998-12-21 | 2006-08-08 | Generex Pharmaceuticals Incorporated | Methods of administering and enhancing absorption of pharmaceutical agents |
US7258850B2 (en) * | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
EP1218049B1 (en) * | 1999-07-12 | 2006-09-20 | Capnia Incorporated | Apparatus for relieving headaches, rhinitis and other common ailments |
US20060172017A1 (en) | 1999-11-08 | 2006-08-03 | Capnia, Incorporated | Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces |
WO2001036018A2 (en) * | 1999-11-08 | 2001-05-25 | Capnia Incorporated | Method and apparatus for relieving ailments using gases to increase the effectiveness of drugs |
US20070039615A1 (en) * | 1999-11-08 | 2007-02-22 | Capnia, Incorporated | Methods and apparatus for treating rhinitis |
WO2001078456A1 (en) * | 2000-04-07 | 2001-10-18 | Ibiden Co., Ltd. | Ceramic heater |
US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
WO2002009669A2 (en) * | 2000-08-01 | 2002-02-07 | Inhale Therapeutic Systems, Inc. | Apparatus and process to produce particles having a narrow size distribution and particles made thereby |
US20020169507A1 (en) * | 2000-12-14 | 2002-11-14 | David Malone | Interbody spine fusion cage |
SE0101204D0 (en) * | 2001-04-04 | 2001-04-04 | Siemens Elema Ab | Heating device for respiratory gas |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US7090830B2 (en) * | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
WO2002094242A1 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan or zolmitriptan through an inhalation route |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
EP1392262A1 (en) * | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
JP4357842B2 (en) * | 2001-05-24 | 2009-11-04 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Delivery of alprazolam, estazolam, midazolam or triazolam by a prescribed inhalation route |
US7458374B2 (en) * | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US20030131843A1 (en) * | 2001-11-21 | 2003-07-17 | Lu Amy T. | Open-celled substrates for drug delivery |
US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
WO2003041693A1 (en) | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
AU2002363947A1 (en) * | 2001-11-21 | 2003-07-24 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
US7523065B2 (en) * | 2001-12-12 | 2009-04-21 | Asset Trust, Inc. | Risk transfer supply chain system |
GB2384184B (en) * | 2002-01-10 | 2005-01-12 | Aea Technology Plc | Cannabis aerosol |
US7582284B2 (en) * | 2002-04-17 | 2009-09-01 | Nektar Therapeutics | Particulate materials |
GB0216562D0 (en) * | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
WO2003094900A1 (en) * | 2002-05-13 | 2003-11-20 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
US20060193788A1 (en) * | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
NZ537142A (en) * | 2002-06-10 | 2008-01-31 | Wyeth Corp | Novel formate salt of O-desmethyl-venlafaxine |
DE10234165B4 (en) * | 2002-07-26 | 2008-01-03 | Advanced Micro Devices, Inc., Sunnyvale | A method of filling a trench formed in a substrate with an insulating material |
US20040076671A1 (en) * | 2002-10-21 | 2004-04-22 | Aletha Tippett | Methods and compositions for topical wound treatment |
US7644715B2 (en) * | 2002-10-31 | 2010-01-12 | Cooltouch, Incorporated | Restless leg syndrome treatment |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
JP2006514633A (en) * | 2002-11-26 | 2006-05-11 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Treatment of headache with antipsychotics delivered by inhalation |
DK1567164T3 (en) * | 2002-11-26 | 2009-05-18 | Alexza Pharmaceuticals Inc | Use of loxapine in the manufacture of a medicament for the treatment of pain |
US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
EP1596824A4 (en) * | 2003-02-04 | 2011-11-23 | Chrysalis Tech Inc | Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem |
WO2005082369A1 (en) * | 2003-02-28 | 2005-09-09 | Delex Therapeutics Inc. | Opioid delivery system |
MXPA05009179A (en) * | 2003-02-28 | 2006-03-08 | Delex Therapeutics Inc | Opioid delivery system. |
US7648981B2 (en) * | 2003-02-28 | 2010-01-19 | Ym Biosciences Inc. | Opioid delivery system |
US7648982B2 (en) * | 2003-02-28 | 2010-01-19 | Ym Biosciences Inc. | Opioid delivery system |
US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
AU2004228757A1 (en) * | 2003-04-14 | 2004-10-21 | Vectura Ltd | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |
EP1625336B9 (en) * | 2003-05-21 | 2012-03-21 | Alexza Pharmaceuticals, Inc. | Use of a layer of solid fuel, method for producing such a layer and associated heating unit |
GB0314149D0 (en) * | 2003-06-18 | 2003-07-23 | Generics Uk Ltd | Novel amorphous forms |
US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
CN2718561Y (en) * | 2003-07-11 | 2005-08-17 | 艾康生物技术(杭州)有限公司 | Protective cover for withdrawing sample label |
NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
US20050042177A1 (en) * | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
EP1656171B9 (en) * | 2003-08-04 | 2010-10-20 | Alexza Pharmaceuticals, Inc. | Substrates for drug delivery device and methods of preparing |
US20050037506A1 (en) * | 2003-08-04 | 2005-02-17 | Alexza Molecular Delivery Corporation | Methods of determining film thicknesses for an aerosol delivery article |
JP2007505136A (en) * | 2003-09-10 | 2007-03-08 | マツプ・フアーマシユーテイカルズ・インコーポレーテツド | Aerosol formulation for delivering dihydroergotamine to systemic circulation by pulmonary inhalation |
KR20060117909A (en) * | 2003-09-15 | 2006-11-17 | 벡투라 리미티드 | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation |
GB2407498B (en) * | 2003-10-30 | 2008-06-11 | Cipla Ltd | Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient |
CN1305266C (en) * | 2003-12-19 | 2007-03-14 | 深圳国人通信有限公司 | Radio local area network cut-in point device based on embedded system |
US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
US20050256553A1 (en) * | 2004-02-09 | 2005-11-17 | John Strisower | Method and apparatus for the treatment of respiratory and other infections using ultraviolet germicidal irradiation |
CN100452898C (en) * | 2004-03-04 | 2009-01-14 | Ut斯达康通讯有限公司 | Method and system for load share in wireless base station |
US7422224B2 (en) * | 2004-04-13 | 2008-09-09 | Kimir Seatpost | Adjustable bicycle seat post assembly |
US7402777B2 (en) * | 2004-05-20 | 2008-07-22 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US20100006092A1 (en) * | 2004-08-12 | 2010-01-14 | Alexza Pharmaceuticals, Inc. | Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages |
US20060039869A1 (en) * | 2004-08-17 | 2006-02-23 | Daniel Wermeling | Intranasal delivery of antipsychotic drugs |
US20060120962A1 (en) * | 2004-10-12 | 2006-06-08 | Rabinowitz Joshua D | Cardiac safe, rapid medication delivery |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
US8691995B2 (en) * | 2004-12-16 | 2014-04-08 | Cipla Limited | Process |
US20060130829A1 (en) * | 2004-12-20 | 2006-06-22 | Sexton Douglas A | Inhalation device |
US7827983B2 (en) * | 2004-12-20 | 2010-11-09 | Hewlett-Packard Development Company, L.P. | Method for making a pharmaceutically active ingredient abuse-prevention device |
AR053237A1 (en) * | 2005-04-21 | 2007-04-25 | Medichem Sa | PROCESS FOR THE PREPARATION OF QUETIAPINE AND QUETIAPINE FUMARATE |
US8062901B2 (en) * | 2005-04-30 | 2011-11-22 | Alere Switzerland Gmbh | Devices and methods for sample collection and analysis |
US20090117660A1 (en) * | 2005-04-30 | 2009-05-07 | Oakville Hong Kong Co., Limited | Devices and methods for sample collection and analysis |
CA2578626C (en) | 2005-06-27 | 2011-07-19 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
EP1909576A4 (en) | 2005-07-29 | 2010-09-01 | Concert Pharmaceuticals Inc | Novel pharmaceutical compounds |
CA2622200A1 (en) * | 2005-09-13 | 2007-03-22 | Elan Pharma International, Limited | Nanoparticulate tadalafil formulations |
US20070092401A1 (en) * | 2005-10-26 | 2007-04-26 | Feier Liao | Devices and methods for sample collection and analysis |
CA2632209C (en) * | 2005-12-01 | 2015-09-29 | Vapore, Inc. | Advanced capillary force vaporizers |
US8357114B2 (en) * | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US9066847B2 (en) | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US9289583B2 (en) | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
AU2006335994A1 (en) | 2006-01-19 | 2007-07-26 | Optinose As | Nasal administration |
US20070183351A1 (en) * | 2006-02-03 | 2007-08-09 | Motorola, Inc. | Method and apparatus for providing service in a multi-ran communication network |
WO2007123945A2 (en) * | 2006-04-21 | 2007-11-01 | Aradigm Corporation | Mechanical single dose intrapulmonary drug delivery devices |
US7909033B2 (en) | 2006-05-03 | 2011-03-22 | Comedica Incorporated | Breathing treatment apparatus |
US8536445B2 (en) * | 2006-06-02 | 2013-09-17 | Emcore Solar Power, Inc. | Inverted metamorphic multijunction solar cells |
US20070299687A1 (en) * | 2006-06-23 | 2007-12-27 | Pamela Palmer | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed |
US8051854B2 (en) * | 2006-09-15 | 2011-11-08 | Comedica Incorporated | Continuous high-frequency oscillation breathing treatment apparatus |
GB0620661D0 (en) * | 2006-10-18 | 2006-11-29 | Pharmasol Ltd | Novel compounds |
US20090270438A1 (en) * | 2006-10-18 | 2009-10-29 | Clive Booles | Novel compositions and formulations |
US20080102097A1 (en) * | 2006-10-31 | 2008-05-01 | Zanella John M | Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent |
US8279765B2 (en) * | 2006-11-13 | 2012-10-02 | Motorola Solutions, Inc. | Method and apparatus for interworking in an inter-technology network |
US20080154374A1 (en) * | 2006-12-20 | 2008-06-26 | Robert David Labrom | Joint implant and a surgical method associated therewith |
WO2008080170A1 (en) * | 2006-12-22 | 2008-07-03 | Alexza Pharmaceuticals, Inc. | Mixed drug aerosol compositiions |
US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
EP2120875B1 (en) | 2007-02-11 | 2018-07-11 | Map Pharmaceuticals Inc. | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
EP2136637B1 (en) | 2007-03-16 | 2015-11-11 | Concert Pharmaceuticals, Inc. | Inhibitors of cholesterol ester transfer protein |
WO2008116165A2 (en) * | 2007-03-21 | 2008-09-25 | Next Safety, Inc. | Methods and systems of delivering medication via inhalation |
US20080261926A1 (en) * | 2007-04-02 | 2008-10-23 | Liu Julie F | Pharmaceutical Calcimimetics |
GB2448183A (en) * | 2007-04-05 | 2008-10-08 | Optinose As | Nasal powder delivery device |
WO2008124585A1 (en) * | 2007-04-06 | 2008-10-16 | Board Of Governors For Higher Education, State Of Rhode Island And Providence Planations | Lowering of proteins associated with alzheimer's disease by interrupting gene transcription with a small molecule |
US8198305B2 (en) * | 2007-04-13 | 2012-06-12 | Concert Pharmaceuticals Inc. | 1,2-benzisoxazol-3-yl compounds |
US7528131B2 (en) * | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
EP2527336A1 (en) | 2007-04-25 | 2012-11-28 | Concert Pharmaceuticals Inc. | Deuterated analogues of cilostazol |
CA3056205C (en) | 2007-05-01 | 2023-09-26 | Concert Pharmaceuticals Inc. | Morphinan compounds |
DK2345653T3 (en) * | 2007-05-01 | 2013-04-08 | Concert Pharmaceuticals Inc | Morphinan compounds |
EP3632916B1 (en) | 2007-05-01 | 2022-06-08 | Concert Pharmaceuticals Inc. | Morphinan compounds |
JP4642134B2 (en) | 2007-05-01 | 2011-03-02 | コンサート ファーマシューティカルズ インコーポレイテッド | Naphthyl (ethyl) acetamide |
WO2008141021A1 (en) * | 2007-05-08 | 2008-11-20 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of tetrahydrotriazolopyrazine compounds and their use as dpp-iv inhibitors |
US9050434B2 (en) * | 2007-05-18 | 2015-06-09 | Comedica Incorporated | Lung therapy device |
CN101711237B (en) | 2007-06-12 | 2013-08-07 | 康塞特制药公司 | Azapeptide derivatives |
CA2702317A1 (en) * | 2007-07-09 | 2009-01-15 | Concert Pharmaceuticals, Inc. | Novel pyrimidinecarboxamide derivatives |
US8442390B2 (en) * | 2007-08-29 | 2013-05-14 | Philip Morris Usa Inc. | Pulsed aerosol generation |
CN101855218A (en) | 2007-09-13 | 2010-10-06 | 康塞特医药品有限公司 | Synthesizing of deuterated catechol and benzo [d] [1,3] dioxole and derivative thereof |
US8470360B2 (en) * | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
US20090104964A1 (en) * | 2007-10-17 | 2009-04-23 | Igt | Gaming system, gaming device and gaming method providing player physical activation of the symbol generator |
US8410124B2 (en) * | 2007-10-18 | 2013-04-02 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
US20090162421A1 (en) * | 2007-12-21 | 2009-06-25 | Paz Arzneimittel-Entwicklungsgesellschaft Mbh | Drugs as well as their production and use in the treatment of pain-associated neuropathies |
US9138430B2 (en) * | 2007-12-27 | 2015-09-22 | Mylan Specialty L.P. | Formulation and method for the release of paroxetine in the large intestine |
WO2009097688A1 (en) * | 2008-02-05 | 2009-08-13 | Clera Inc. | Compositions and methods for alleviating depression or improving cognition |
EP2247330B1 (en) | 2008-02-07 | 2017-09-20 | The University of Washington | Circumferential aerosol device |
EP2265334A2 (en) | 2008-02-29 | 2010-12-29 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
MX2010009765A (en) | 2008-03-06 | 2013-07-12 | Anacor Pharmaceuticals Inc | Boron-containing small molecules as anti-inflammatory agents. |
US8201752B2 (en) * | 2008-03-10 | 2012-06-19 | Vapore, Inc. | Low energy vaporization of liquids: apparatus and methods |
US20090264489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation |
US9132085B2 (en) * | 2008-04-18 | 2015-09-15 | Warsaw Orthopedic, Inc. | Compositions and methods for treating post-operative pain using clonidine and bupivacaine |
US8557273B2 (en) | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
US20090263489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US9132119B2 (en) * | 2008-04-18 | 2015-09-15 | Medtronic, Inc. | Clonidine formulation in a polyorthoester carrier |
US8420114B2 (en) * | 2008-04-18 | 2013-04-16 | Warsaw Orthopedic, Inc. | Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation |
US8722079B2 (en) * | 2008-04-18 | 2014-05-13 | Warsaw Orthopedic, Inc. | Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine |
US8889173B2 (en) * | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
US8883768B2 (en) * | 2008-04-18 | 2014-11-11 | Warsaw Orthopedic, Inc. | Fluocinolone implants to protect against undesirable bone and cartilage destruction |
US9072727B2 (en) * | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
US8956641B2 (en) * | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
US8946277B2 (en) | 2008-04-18 | 2015-02-03 | Warsaw Orthopedic, Inc. | Clonidine formulations in a biodegradable polymer carrier |
US8629172B2 (en) | 2008-04-18 | 2014-01-14 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
US20090263451A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain |
US9610243B2 (en) | 2008-04-18 | 2017-04-04 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US20090264477A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc., An Indiana Corporation | Beta adrenergic receptor agonists for treatment of pain and/or inflammation |
US9649469B2 (en) | 2008-04-24 | 2017-05-16 | The Invention Science Fund I Llc | Methods and systems for presenting a combination treatment |
US9282927B2 (en) | 2008-04-24 | 2016-03-15 | Invention Science Fund I, Llc | Methods and systems for modifying bioactive agent use |
US9560967B2 (en) | 2008-04-24 | 2017-02-07 | The Invention Science Fund I Llc | Systems and apparatus for measuring a bioactive agent effect |
US9449150B2 (en) | 2008-04-24 | 2016-09-20 | The Invention Science Fund I, Llc | Combination treatment selection methods and systems |
US20100017001A1 (en) * | 2008-04-24 | 2010-01-21 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational system and method for memory modification |
US9662391B2 (en) | 2008-04-24 | 2017-05-30 | The Invention Science Fund I Llc | Side effect ameliorating combination therapeutic products and systems |
ES2419204T3 (en) * | 2008-05-27 | 2013-08-19 | The University Of Melbourne | Methods to treat mammals with eustachian tube dysfunctions |
US7845277B2 (en) * | 2008-05-28 | 2010-12-07 | Autoliv Asp, Inc. | Header assembly |
US20110160253A1 (en) * | 2008-05-28 | 2011-06-30 | Harbeson Scott L | Deuterated tizanidine |
US20100221221A1 (en) * | 2008-08-12 | 2010-09-02 | Concert Pharmaceuticals Inc. | N-phenyl-2-pyrimidineamine derivatives |
EP2334686B1 (en) | 2008-08-28 | 2019-02-27 | President and Fellows of Harvard College | Cortistatin analogues and syntheses therof |
US7834295B2 (en) | 2008-09-16 | 2010-11-16 | Alexza Pharmaceuticals, Inc. | Printable igniters |
US20100065052A1 (en) * | 2008-09-16 | 2010-03-18 | Alexza Pharmaceuticals, Inc. | Heating Units |
MX2011002994A (en) | 2008-09-19 | 2011-05-30 | Concert Pharmaceuticals Inc | Morphinan compounds. |
US20100098746A1 (en) * | 2008-10-20 | 2010-04-22 | Warsaw Orthopedic, Inc. | Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone |
EP2364151A1 (en) | 2008-10-30 | 2011-09-14 | Concert Pharmaceuticals Inc. | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury |
WO2010062692A1 (en) | 2008-10-30 | 2010-06-03 | Concert Pharmaceuticals Inc. | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury |
US8198268B2 (en) * | 2008-10-31 | 2012-06-12 | Janssen Biotech, Inc. | Tianeptine sulfate salt forms and methods of making and using the same |
US9096646B2 (en) | 2008-11-04 | 2015-08-04 | Anchor Therapeutics, Inc. | CXCR4 receptor compounds |
US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
WO2010065547A1 (en) * | 2008-12-01 | 2010-06-10 | Map Pharmaceuticals, Inc. | Inhalation delivery methods and devices |
US8822546B2 (en) * | 2008-12-01 | 2014-09-02 | Medtronic, Inc. | Flowable pharmaceutical depot |
WO2010065755A1 (en) | 2008-12-04 | 2010-06-10 | Concert Pharmaceuticals, Inc. | Deuterated pyridinones |
WO2010074753A1 (en) * | 2008-12-23 | 2010-07-01 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
US20100163033A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US20100168602A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc | Methods and systems for presenting an inhalation experience |
US8706518B2 (en) * | 2008-12-30 | 2014-04-22 | The Invention Science Fund I, Llc | Methods and systems for presenting an inhalation experience |
US20100163025A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc | Methods and systems for presenting an inhalation experience |
US20100163034A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US20100163036A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US8694330B2 (en) * | 2008-12-30 | 2014-04-08 | The Invention Science Fund I, Llc | Methods and systems for presenting an inhalation experience |
US8738395B2 (en) * | 2008-12-30 | 2014-05-27 | The Invention Science Fund I, Llc | Methods and systems for presenting an inhalation experience |
US20100163027A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US8712794B2 (en) * | 2008-12-30 | 2014-04-29 | The Invention Science Fund I, Llc | Methods and systems for presenting an inhalation experience |
US20100169259A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US8725529B2 (en) | 2008-12-30 | 2014-05-13 | The Invention Science Fund I, Llc | Methods and systems for presenting an inhalation experience |
US20100169260A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc | Methods and systems for presenting an inhalation experience |
US20100163024A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation | Methods and systems for presenting an inhalation experience |
US20100168529A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US20100163038A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US20100166613A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US20100168525A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US20110053961A1 (en) | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
US20100228097A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Methods and compositions to diagnose pain |
EP2229980B1 (en) * | 2009-03-16 | 2015-08-12 | Nuvolase, Inc. | Treatment of microbiological pathogens in a toe nail with antimicrobial light |
WO2010107791A2 (en) | 2009-03-17 | 2010-09-23 | Concert Pharmaceuticals, Inc. | Pyrazinoisoquinoline compounds |
EP2413902B1 (en) * | 2009-03-18 | 2019-07-17 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
WO2010107761A1 (en) | 2009-03-18 | 2010-09-23 | Acelrx Pharmaceuticals, Inc. | Improved storage and dispensing devices for administration of oral transmucosal dosage forms |
US20100239632A1 (en) * | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
WO2010138889A1 (en) | 2009-05-28 | 2010-12-02 | Concert Pharmaceuticals, Inc. | Peptides for the treatment of hcv infections |
US20100300433A1 (en) * | 2009-05-28 | 2010-12-02 | Alexza Pharmaceuticals, Inc. | Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol |
RS53357B (en) | 2009-06-18 | 2014-10-31 | Concert Pharmaceuticals Inc. | Deuterated isoindoline-1,3-dione derivatives as pde4 and tnf-alpha inhibitors |
EP2454259A1 (en) | 2009-06-23 | 2012-05-23 | Concert Pharmaceuticals Inc. | Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators |
WO2010151804A1 (en) * | 2009-06-26 | 2010-12-29 | Map Pharmaceuticals, Inc. | Administration of dihydroergotamine mesylate particles using a metered dose inhaler |
US8617583B2 (en) * | 2009-07-17 | 2013-12-31 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis |
US20110015154A1 (en) * | 2009-07-20 | 2011-01-20 | Kellermann Gottfried H | Supporting acetylcholine function |
US8814922B2 (en) * | 2009-07-22 | 2014-08-26 | New Star Lasers, Inc. | Method for treatment of fingernail and toenail microbial infections using infrared laser heating and low pressure |
US8231891B2 (en) * | 2009-07-31 | 2012-07-31 | Warsaw Orthopedic, Inc. | Implantable drug depot for weight control |
US10758582B2 (en) * | 2009-08-17 | 2020-09-01 | Xten Capital Group, Inc. | Vaporized medicants and methods of use |
US8368883B2 (en) * | 2009-09-09 | 2013-02-05 | Sensa Bues Ab | System and method for detection of analytes in exhaled breath |
NZ599202A (en) | 2009-10-13 | 2014-05-30 | Philip Morris Prod | Air freshening device |
US8278460B2 (en) | 2009-10-15 | 2012-10-02 | Concert Pharmaceuticals, Inc. | Substituted benzimidazoles |
US20110097375A1 (en) | 2009-10-26 | 2011-04-28 | Warsaw Orthopedic, Inc. | Formulation for preventing or reducing bleeding at a surgical site |
US20110098265A1 (en) * | 2009-10-28 | 2011-04-28 | Neuroscience, Inc. | Methods for reducing cravings and impulses associated with addictive and compulsive behaviors |
US9151425B2 (en) * | 2009-11-02 | 2015-10-06 | Comedica Incorporated | Multiple conduit connector apparatus and method |
US20110100360A1 (en) * | 2009-11-02 | 2011-05-05 | Joseph Dee Faram | Composite lung therapy device and method |
WO2011094450A1 (en) | 2010-01-27 | 2011-08-04 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules |
US20140018379A1 (en) | 2010-02-18 | 2014-01-16 | Concert Pharmaceuticals Inc. | Pyrimidine derivatives |
EP2566494B1 (en) | 2010-02-26 | 2017-11-29 | Acer Therapeutics, Inc. | Cxcr4 receptor compounds |
US8513434B2 (en) | 2010-03-02 | 2013-08-20 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives |
US8575361B2 (en) | 2010-03-02 | 2013-11-05 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives |
US9107922B2 (en) | 2010-07-16 | 2015-08-18 | Concert Pharmaceuticals, Inc. | Pyrimidinecarboxamide derivatives |
US20130142868A1 (en) * | 2010-08-20 | 2013-06-06 | University Of Washington | Circumferential Aerosol Device for Delivering Drugs to Olfactory Epithelium and Brain |
US20120048963A1 (en) | 2010-08-26 | 2012-03-01 | Alexza Pharmaceuticals, Inc. | Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter |
EA033311B1 (en) | 2010-09-07 | 2019-09-30 | Анакор Фармасьютикалс, Инк. | Benzoxaborole derivatives as antibacterial agents |
DE102010041840A1 (en) * | 2010-10-01 | 2012-04-05 | Bayerische Motoren Werke Aktiengesellschaft | Method for producing a ventilation bore in a bearing block of a crankcase of a reciprocating internal combustion engine |
WO2012079075A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Deuterated phthalimide derivatives |
PL2654864T3 (en) | 2010-12-22 | 2021-07-12 | Syqe Medical Ltd. | System for drug delivery |
US8447329B2 (en) | 2011-02-08 | 2013-05-21 | Longsand Limited | Method for spatially-accurate location of a device using audio-visual information |
CA2828884C (en) | 2011-03-03 | 2021-04-27 | Impel Neuropharma, Inc. | Nasal drug delivery device |
WO2012129381A1 (en) | 2011-03-22 | 2012-09-27 | Concert Pharmaceuticals Inc. | Deuterated preladenant |
WO2012151361A1 (en) | 2011-05-03 | 2012-11-08 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
US20140072621A1 (en) | 2011-05-09 | 2014-03-13 | The Cleveland Clinic Foundation | Composition and method to improve intestinal health |
RU2618084C2 (en) | 2011-05-09 | 2017-05-02 | Импел Ньюрофарма Инк. | Tips for nasal drug delivery |
WO2012154728A1 (en) | 2011-05-10 | 2012-11-15 | Concert Pharmaceuticals Inc. | Deuterated n-butyl bumetanide |
JP6063455B2 (en) | 2011-05-18 | 2017-01-18 | コンサート ファーマシューティカルズ インコーポレイテッド | Deuterated derivatives of Ibakaftor |
CN104254540A (en) | 2012-01-09 | 2014-12-31 | 安科治疗公司 | APJ receptor compounds |
WO2013130849A1 (en) | 2012-02-29 | 2013-09-06 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
WO2013145632A1 (en) * | 2012-03-30 | 2013-10-03 | 日本電気株式会社 | Flow line data analysis device, system, program and method |
WO2013155465A1 (en) | 2012-04-13 | 2013-10-17 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
WO2013159026A1 (en) | 2012-04-20 | 2013-10-24 | Concert Pharmaceuticals, Inc. | Deuterated rigosertib |
MX360495B (en) | 2012-06-15 | 2018-11-06 | Concert Pharmaceuticals Inc | Deuterated derivatives of ruxolitinib. |
EP2885267B1 (en) | 2012-07-12 | 2018-09-05 | Concert Pharmaceuticals, Inc. | Deuterated idebenone |
EA031716B1 (en) | 2012-08-17 | 2019-02-28 | Консерт Фармасьютикалс, Инк. | Deuterated baricitinib |
EP2711006A1 (en) | 2012-09-21 | 2014-03-26 | Basil Rigas | Product Comprising a Nicotine-Containing Material and an Anti-Cancer Agent |
MY178621A (en) | 2012-11-19 | 2020-10-19 | Vertex Pharmaceuticals Europe Ltd | Deuterated cftr potentiators |
US10034988B2 (en) | 2012-11-28 | 2018-07-31 | Fontem Holdings I B.V. | Methods and devices for compound delivery |
US9795752B2 (en) | 2012-12-03 | 2017-10-24 | Mhs Care-Innovation, Llc | Combination respiratory therapy device, system, and method |
JP2016503798A (en) | 2012-12-20 | 2016-02-08 | コンサート ファーマシューティカルズ インコーポレイテッド | Deuterated ALK inhibitor |
US9757529B2 (en) * | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
US9186860B2 (en) * | 2013-01-28 | 2015-11-17 | Carl D. Luenser | Vaporizer kit for tobacco, medications, and the like |
MX2015012741A (en) | 2013-03-15 | 2016-02-19 | Concert Pharmaceuticals Inc | Deuterated palbociclib. |
EP2968268B1 (en) | 2013-03-15 | 2020-07-29 | Concert Pharmaceuticals Inc. | Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
HU231191B1 (en) | 2013-04-15 | 2021-08-30 | Szegedi Tudományegyetem | Isotope containing morphine molecules |
US10537692B2 (en) | 2013-04-28 | 2020-01-21 | Impel Neuropharma, Inc. | Medical unit dose container |
US10149823B2 (en) | 2013-04-30 | 2018-12-11 | Otitopic Inc. | Dry powder formulations and methods of use |
CN104274427A (en) * | 2013-07-03 | 2015-01-14 | 陆克塞纳医药公司 | Novel aerosol formulations of granisetron and uses thereof |
CN104274426A (en) | 2013-07-03 | 2015-01-14 | 陆克塞纳医药公司 | Novel aerosol formulations of ondansetron and uses thereof |
JP6397493B2 (en) | 2013-07-11 | 2018-09-26 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Nicotine salt with meta-salicylic acid |
WO2015009889A1 (en) | 2013-07-18 | 2015-01-22 | Concert Pharmaceuticals, Inc. | Deuterated intedanib derivatives and their use for the treatment of proliferative disorders |
US20160159861A1 (en) | 2013-07-18 | 2016-06-09 | Anchor Therapeutics, Inc. | APJ Receptor Compounds |
MX348595B (en) | 2013-08-02 | 2017-06-21 | Laboratorio Raam De Sahuayo S A De C V | Pharmaceutical composition with anti-inflammatory agents and production process thereof. |
WO2015031741A1 (en) | 2013-08-30 | 2015-03-05 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor |
US10194693B2 (en) | 2013-09-20 | 2019-02-05 | Fontem Holdings 1 B.V. | Aerosol generating device |
US9364815B2 (en) * | 2013-11-07 | 2016-06-14 | Saudi Basic Industries Corporation | Method of preparing an alumina catalyst support and catalyst for dehydrogenation reactions, and its use |
EP3082816B1 (en) | 2013-12-20 | 2019-03-20 | Indivior UK Limited | Intranasal naloxone compositions and methods of making and using same |
CA2934819A1 (en) | 2013-12-24 | 2015-07-02 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
SI3639828T1 (en) | 2013-12-24 | 2022-04-29 | Virginia Commonwealth University | Use of oxygenated cholesterol sulfates (ocs) for treating acute liver failure |
US9220294B2 (en) | 2014-02-11 | 2015-12-29 | Timothy McCullough | Methods and devices using cannabis vapors |
US10821240B2 (en) | 2014-02-11 | 2020-11-03 | Vapor Cartridge Technology Llc | Methods and drug delivery devices using cannabis |
US9380813B2 (en) | 2014-02-11 | 2016-07-05 | Timothy McCullough | Drug delivery system and method |
DK3107548T3 (en) | 2014-02-20 | 2022-07-18 | Otitopic Inc | DRY POWDER FORMULATIONS FOR INHALATION |
WO2015138352A1 (en) * | 2014-03-10 | 2015-09-17 | Tiger Tool International Incorporated | Heating and cooling systems and methods for truck cabs |
WO2015148649A2 (en) * | 2014-03-26 | 2015-10-01 | Basil Rigas | Systems and methods for ameliorating the effects of tobacco products |
WO2015155544A1 (en) * | 2014-04-10 | 2015-10-15 | Patrick Crowley | Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders |
WO2015179772A1 (en) | 2014-05-23 | 2015-11-26 | Concert Pharmaceuticals, Inc. | Deuterated phenylquinazolinone and phenylisoquinolinone compounds |
WO2015188073A1 (en) | 2014-06-06 | 2015-12-10 | Research Triangle Institute | Apelin receptor (apj) agonists and uses thereof |
JP2015229527A (en) * | 2014-06-09 | 2015-12-21 | 三光機械株式会社 | Multi-row type automatic packing machine |
EP3160553B1 (en) | 2014-06-30 | 2021-10-20 | Syqe Medical Ltd. | Device for vaporization and inhalation of isolated substances |
US11298477B2 (en) | 2014-06-30 | 2022-04-12 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
CN106573123B (en) | 2014-06-30 | 2021-08-31 | Syqe医药有限公司 | Methods, devices, and systems for pulmonary delivery of active agents |
CN106604755B (en) | 2014-06-30 | 2020-08-11 | Syqe医药有限公司 | Inhaler device with flow regulation |
EP3939639A1 (en) | 2014-06-30 | 2022-01-19 | Syqe Medical Ltd. | Drug dose cartridge for an inhaler device |
AU2015283590B2 (en) | 2014-06-30 | 2020-04-16 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
NZ730560A (en) | 2014-09-29 | 2020-05-29 | Zogenix International Ltd | Control system for control of distribution of medication |
WO2016061488A1 (en) | 2014-10-17 | 2016-04-21 | Concert Pharmaceuticals, Inc. | Amine reuptake inhibitors |
WO2016073545A1 (en) | 2014-11-06 | 2016-05-12 | Concert Pharmaceuticals, Inc. | Phenyloxadiazole benzoic acids |
WO2016089814A1 (en) | 2014-12-02 | 2016-06-09 | Concert Pharmaceuticals, Inc. | Deuterated analogues of daclatasvir |
SG11201704797TA (en) | 2014-12-23 | 2017-07-28 | Acelrx Pharmaceuticals Inc | Systems, devices and methods for dispensing oral transmucosal dosage forms |
WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
WO2016109795A1 (en) | 2014-12-31 | 2016-07-07 | Concert Pharmaceuticals, Inc. | Deuterated funapide and difluorofunapide |
CN107405346A (en) | 2015-01-20 | 2017-11-28 | Xoc制药股份有限公司 | Different ergoline compound and application thereof |
WO2016118540A1 (en) * | 2015-01-20 | 2016-07-28 | Xoc Pharmaceuticals, Inc. | Treating and/or preventing emesis and/or nausea including acute and/or delayed nausea and/or emesis |
US9657020B2 (en) | 2015-01-20 | 2017-05-23 | Xoc Pharmaceuticals, Inc. | Ergoline compounds and uses thereof |
WO2016144830A1 (en) | 2015-03-06 | 2016-09-15 | Concert Pharmaceuticals, Inc. | Deuterated emricasan |
CN114522307A (en) | 2015-03-11 | 2022-05-24 | 艾利斯达医药品公司 | Use of antistatic materials in airways for hot aerosol condensation processes |
AU2016243171B2 (en) | 2015-03-31 | 2020-10-08 | Concert Pharmaceuticals, Inc. | Deuterated VX-661 |
EP3277351B1 (en) | 2015-04-02 | 2019-06-05 | Hill-Rom Services PTE. LTD. | Manifold for respiratory device |
US10683305B2 (en) | 2015-04-27 | 2020-06-16 | Concert Pharmaceuticals, Inc. | Deuterated OTX-015 |
EP3294298A4 (en) | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
WO2017003469A1 (en) * | 2015-06-30 | 2017-01-05 | University Of South Florida | Inhibitors of the fkbp51 protein from a high-throughput drug screen and methods of use |
WO2017004411A1 (en) | 2015-07-01 | 2017-01-05 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
KR20180052566A (en) | 2015-07-02 | 2018-05-18 | 키비타스 테라퓨틱스, 인코포레이티드. | Tripentad powder for pulmonary delivery |
WO2017020005A1 (en) | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Morphinan compounds for use in treating agitation |
CA2994169A1 (en) | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
US11266799B2 (en) | 2015-09-10 | 2022-03-08 | Impel Neuropharma, Inc. | In-line nasal delivery device |
WO2017087795A1 (en) | 2015-11-19 | 2017-05-26 | Concert Pharmaceuticals, Inc. | Deuterated epi-743 |
US10100059B2 (en) | 2015-12-09 | 2018-10-16 | Research Triangle Institute | Apelin receptor (APJ) agonists and uses thereof |
EP3393470B1 (en) | 2015-12-22 | 2021-01-20 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
JP6893213B2 (en) * | 2015-12-22 | 2021-06-23 | ゾゲニクス インターナショナル リミテッド | Norfenfluramine composition and its preparation method |
US10092036B2 (en) * | 2015-12-28 | 2018-10-09 | Rai Strategic Holdings, Inc. | Aerosol delivery device including a housing and a coupler |
AU2017204945B2 (en) | 2016-01-06 | 2022-11-10 | Syqe Medical Ltd. | Low dose therapeutic treatment |
IL260335B2 (en) | 2016-02-01 | 2023-10-01 | Incarda Therapeutics Inc | Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation |
US20170216220A1 (en) * | 2016-02-03 | 2017-08-03 | Intelgenx Corp. | Loxapine film oral dosage form |
WO2017147003A1 (en) | 2016-02-26 | 2017-08-31 | Novobiotic Pharmaceuticals, Llc | Novel macrocyclic antibiotics and uses thereof |
AU2017286715B2 (en) | 2016-06-15 | 2022-03-03 | The General Hospital Corporation | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions |
US10730841B2 (en) | 2016-07-04 | 2020-08-04 | Avanir Pharmaceuticals, Inc. | Methods for the synthesis of deuterated dextromethorphan |
JP7178341B2 (en) | 2016-08-01 | 2022-11-25 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | Particles for protein and peptide delivery |
KR20190040237A (en) | 2016-08-24 | 2019-04-17 | 조게닉스 인터내셔널 리미티드 | Agents for inhibiting the formation of 5-HT2B agonists and methods for their use |
DE102016221705B4 (en) | 2016-11-07 | 2018-05-17 | Schaeffler Technologies AG & Co. KG | Gear from a gear assembly and method for producing a gear assembly |
US20180185347A1 (en) * | 2016-11-16 | 2018-07-05 | Transition Therapeutics (Ireland 2) Limited | Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp |
EP4272827A3 (en) | 2016-12-09 | 2024-01-24 | Alexza Pharmaceuticals, Inc. | Method of treating epilepsy |
FI3698791T3 (en) | 2017-02-02 | 2024-01-11 | Otolanum Ag | Intranasal composition comprising betahistine |
EP3592393B1 (en) | 2017-03-10 | 2021-12-01 | QuiaPEG Pharmaceuticals AB | Releasable conjugates |
US20200129504A1 (en) | 2017-03-13 | 2020-04-30 | Beyondspring Pharmaceuticals, Inc. | Compositions of plinabulin and use thereof |
AU2018266199A1 (en) | 2017-05-10 | 2019-11-07 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
CN111094282B (en) | 2017-05-19 | 2023-06-16 | 智优有限公司 | Derivatives of resiquimod |
JP2020522504A (en) | 2017-06-01 | 2020-07-30 | エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc | Polycyclic compounds and their uses |
WO2018232252A1 (en) | 2017-06-15 | 2018-12-20 | Mayo Foundation For Medical Education And Research | Methods to treat gliomas using a stat3 inhibitor |
US11396516B2 (en) | 2017-06-16 | 2022-07-26 | The General Hospital Corporation | Tricyclic compounds as Cyp1 inhibitors |
US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
CN109391578B (en) * | 2017-08-11 | 2022-07-22 | 华为技术有限公司 | Signal sending method, signal receiving method, terminal equipment and network equipment |
US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
AU2018352382B2 (en) | 2017-10-16 | 2022-06-02 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
US11395887B2 (en) | 2017-11-21 | 2022-07-26 | Impel Pharmaceuticals Inc. | Intranasal device with inlet interface |
EP3713628A4 (en) | 2017-11-21 | 2021-08-18 | Impel Neuropharma Inc. | Intranasal device with dip tube |
ES2937440T3 (en) | 2018-01-05 | 2023-03-28 | Impel Pharmaceuticals Inc | Intranasal administration of dihydroergotamine using a precision olfactory device |
KR20200118034A (en) | 2018-01-05 | 2020-10-14 | 임펠 뉴로파마 인코포레이티드 | Intranasal delivery of olanzapine by a precision olfactory organ device |
EP3745862A4 (en) | 2018-01-31 | 2021-04-07 | Mayo Foundation for Medical Education and Research | Methods of treating fibrotic pathologies |
EP3768378A4 (en) | 2018-03-22 | 2021-11-17 | InCarda Therapeutics, Inc. | A novel method to slow ventricular rate |
US11571397B2 (en) | 2018-05-11 | 2023-02-07 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
EP3818981B1 (en) | 2018-07-04 | 2024-02-21 | Amézcua Amézcua, Federico | Synergic pharmaceutical composition of the active enantiomer (s)-ketorolac and gabapentin for the treatment of neuropathic pain |
AU2019299234A1 (en) | 2018-07-05 | 2021-01-14 | Mayo Foundation For Medical Education And Research | PIKfyve inhibitors |
JP2021532098A (en) | 2018-07-19 | 2021-11-25 | インペル ニューロファーマ インコーポレイテッド | Respiratory tract delivery of levodopa and dopa decarboxylase inhibitors for the treatment of Parkinson's disease |
WO2020036478A2 (en) | 2018-08-13 | 2020-02-20 | AMÉZCUA AMÉZCUA, Federico | Synergistic pharmaceutical composition comprising aceclofenac and betamethasone for the treatment of pain in localised forms of rheumatic illnesses |
US11090449B2 (en) | 2018-08-21 | 2021-08-17 | Vivera Pharmaceuticals Inc. | Smart inhaler device with automated dose delivery, measurement, and management |
US11083850B2 (en) | 2018-08-21 | 2021-08-10 | Vivera Pharmaceuticals Inc. | Secure smart dosing system with automated delivery, measurement, and management |
AU2019340472A1 (en) | 2018-09-12 | 2021-04-01 | Quiapeg Pharmaceuticals Ab | Releasable GLP-1 conjugates |
BR112021012950A2 (en) | 2019-01-03 | 2021-09-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | METHODS AND MATERIALS TO INCREASE EB TRANSCRIPTION FACTOR POLYPEPTIDE LEVELS |
CA3125430A1 (en) | 2019-01-03 | 2020-07-09 | Impel Neuropharma, Inc. | Nasal drug delivery device |
MX2019000312A (en) | 2019-01-08 | 2019-10-09 | Federico Amezcua Amezcua | A synergistic pharmaceutical composition of aceclofenac and betamethasone for the treatment of pain of rheumatic affections or post-surgical pain. |
CN109674773A (en) * | 2019-02-22 | 2019-04-26 | 南京中医药大学 | A kind of 'Xiduofeng ' drug microparticles of pulmonary administration and the preparation method and application thereof |
US11878109B2 (en) | 2019-05-17 | 2024-01-23 | Impel Pharmaceuticals Inc. | Single-use nasal delivery device |
CA3148598A1 (en) | 2019-07-30 | 2021-02-04 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating fibrotic pathologies |
US11020384B2 (en) | 2019-08-01 | 2021-06-01 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
US11364225B2 (en) | 2019-08-21 | 2022-06-21 | Bn Intellectual Properties, Inc. | Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same |
MX2022003189A (en) | 2019-09-16 | 2022-06-08 | Vapor Cartridge Tech Llc | Drug delivery system with stackable substrates. |
EP3868364A1 (en) | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
US11071739B1 (en) | 2020-09-29 | 2021-07-27 | Genus Lifesciences Inc. | Oral liquid compositions including chlorpromazine |
US20220117916A1 (en) * | 2020-10-19 | 2022-04-21 | SafeRx Pharmaceuticals, LLC | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose |
EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
WO2023063381A1 (en) * | 2021-10-14 | 2023-04-20 | 静岡県公立大学法人 | Powder drug formulation |
IT202100031637A1 (en) | 2021-12-17 | 2023-06-17 | Universita’ Degli Studi Di Parma | DUST FOR INHALATION AND PRODUCTION PROCEDURE |
EP4349175A1 (en) | 2022-10-05 | 2024-04-10 | The Procter & Gamble Company | Antimicrobial composition comprising a modified alkyl glycoside and an organic acid |
Family Cites Families (273)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US32638A (en) * | 1861-06-25 | Boot-heel | ||
US113557A (en) * | 1871-04-11 | Improvement in metal screws and nuts | ||
US30285A (en) * | 1860-10-09 | Fruit-drier | ||
US58009A (en) * | 1866-09-11 | Improved condenser | ||
GB502761A (en) | 1938-01-29 | 1939-03-24 | Christopher Engelbreth | Improvements in and relating to hand inhalation apparatus |
US2902484A (en) | 1954-04-27 | 1959-09-01 | Rhone Poulenc Sa | Phenthiazine derivatives and processes for their preparation |
US3474101A (en) | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
NL135583C (en) | 1961-10-10 | |||
GB972363A (en) | 1962-08-18 | 1964-10-14 | Rambold Adolf | Wrapper band for teabag or the like |
US3169095A (en) | 1962-10-30 | 1965-02-09 | Rexall Drug Chemical | Self-propelling powder-dispensing compositions |
NL289785A (en) | 1962-11-29 | |||
GB1063512A (en) | 1962-11-30 | 1967-03-30 | Benger Lab Ltd | Aerosols |
US3456247A (en) * | 1966-01-14 | 1969-07-15 | Ibm | Coupled film storage device |
IL26896A (en) | 1966-01-19 | 1970-11-30 | Endo Lab | 14-hydroxynormorphines and 14-hydroxynormorphinones |
US3987052A (en) | 1969-03-17 | 1976-10-19 | The Upjohn Company | 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines |
USRE30285E (en) | 1972-05-22 | 1980-05-27 | Spraying devices, in particular nebulizing devices | |
US3949743A (en) | 1973-03-19 | 1976-04-13 | Schick Incorporated | Medicated vapor production method and apparatus |
US3982095A (en) | 1973-10-04 | 1976-09-21 | Searle Cardio-Pulmonary Systems Inc. | Respiratory humidifier |
US3894040A (en) | 1974-09-16 | 1975-07-08 | American Home Prod | 2,5,6,7-Tetrahydro-3H-imidazo(1,2-D)(1,4)benzodiazepine-5,6-dicarboxylic acid esters |
US4121583A (en) | 1976-07-13 | 1978-10-24 | Wen Yuan Chen | Method and apparatus for alleviating asthma attacks |
US4141369A (en) | 1977-01-24 | 1979-02-27 | Burruss Robert P | Noncombustion system for the utilization of tobacco and other smoking materials |
SE7812207L (en) | 1977-12-01 | 1979-06-02 | Welsh Nat School Med | APPARATUS, PROCEDURE AND MANUFACTURED PRODUCTS FOR USE IN THE ADMINISTRATION OF ANTIHISTAMINES |
US4183912A (en) | 1978-01-16 | 1980-01-15 | American Home Products Corporation | Inhalation therapy for relieving bronchial spasm using quaternary salts of promethazine |
US4484451A (en) * | 1978-09-05 | 1984-11-27 | United Air Specialists, Inc. | Two-stage gas condenser with feedback cooling |
IL59407A (en) | 1979-03-06 | 1983-12-30 | Sanofi Sa | Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them |
US4654370A (en) | 1979-03-12 | 1987-03-31 | Abbott Laboratories | Glyceryl valproates |
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
ATE3774T1 (en) | 1980-05-02 | 1983-06-15 | Schering Corporation | BECLOMETHASONE ESTER SOLVATE, PROCESS FOR THEIR PREPARATION AND PREPARATION OF A FORMULATION. |
US4303083A (en) | 1980-10-10 | 1981-12-01 | Burruss Jr Robert P | Device for evaporation and inhalation of volatile compounds and medications |
US4376767A (en) | 1981-01-02 | 1983-03-15 | Merck & Co., Inc. | Pyridylmethyl esters of selected bio-affecting carboxylic acids |
DE3116951C2 (en) * | 1981-04-29 | 1984-12-20 | Drägerwerk AG, 2400 Lübeck | Device for adding liquid anesthetics to the breathing gas to be supplied to the patient |
DE3224849A1 (en) * | 1982-07-02 | 1984-01-05 | Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn | STEAM INHALER |
US4508726A (en) | 1982-09-16 | 1985-04-02 | The Upjohn Company | Treatment of panic disorders with alprazolam |
US4474191A (en) | 1982-09-30 | 1984-10-02 | Steiner Pierre G | Tar-free smoking devices |
DE3390229C2 (en) | 1982-09-30 | 1987-10-01 | Dainippon Jochugiku Kk | Thermal evaporator for chemicals |
US4753758A (en) | 1983-05-19 | 1988-06-28 | Intertech Resources Inc. | Respiratory humidifier |
DE3326089A1 (en) | 1983-07-20 | 1985-02-07 | Gödecke AG, 1000 Berlin | INHALATION-INTENDED PHARMACEUTICAL FORM OF CALCIUM ANTAGONISTS |
AU591451B2 (en) | 1983-08-01 | 1989-12-07 | Mclean Hospital Corporation, The | Gamma amino butyric acid esters |
US4588721A (en) | 1983-09-12 | 1986-05-13 | The Upjohn Company | Treatment of negative symptoms of schizophrenia |
US4566552A (en) * | 1983-11-16 | 1986-01-28 | International Harvester Company | Hood tilt retardation system |
US4683231A (en) | 1984-03-02 | 1987-07-28 | Research Foundation For Mental Hygiene, Inc. | Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking |
US5042509A (en) | 1984-09-14 | 1991-08-27 | R. J. Reynolds Tobacco Company | Method for making aerosol generating cartridge |
US4793365A (en) | 1984-09-14 | 1988-12-27 | R. J. Reynolds Tobacco Company | Smoking article |
US5020548A (en) | 1985-08-26 | 1991-06-04 | R. J. Reynolds Tobacco Company | Smoking article with improved fuel element |
US5067499A (en) | 1984-09-14 | 1991-11-26 | R. J. Reynolds Tobacco Company | Smoking article |
US4854331A (en) | 1984-09-14 | 1989-08-08 | R. J. Reynolds Tobacco Company | Smoking article |
CN1018607B (en) | 1984-12-21 | 1992-10-14 | 美国耳·杰·瑞诺兹烟草公司 | Smoking article |
US4928714A (en) | 1985-04-15 | 1990-05-29 | R. J. Reynolds Tobacco Company | Smoking article with embedded substrate |
DE3686025T2 (en) | 1985-05-22 | 1993-01-07 | Liposome Technology Inc | METHOD AND SYSTEM FOR INHALING LIPOSOMES. |
US4989619A (en) | 1985-08-26 | 1991-02-05 | R. J. Reynolds Tobacco Company | Smoking article with improved fuel element |
US5060666A (en) | 1985-10-28 | 1991-10-29 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
US5033483A (en) | 1985-10-28 | 1991-07-23 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
US4756318A (en) | 1985-10-28 | 1988-07-12 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
JPS62204756A (en) * | 1986-03-04 | 1987-09-09 | 大研医工株式会社 | Drug volatilizing method and apparatus |
DE3767615D1 (en) | 1986-03-10 | 1991-02-28 | Kurt Burghart | PHARMACEUTICAL AND METHOD FOR THE PRODUCTION THEREOF. |
US4708151A (en) | 1986-03-14 | 1987-11-24 | R. J. Reynolds Tobacco Company | Pipe with replaceable cartridge |
US4771795A (en) | 1986-05-15 | 1988-09-20 | R. J. Reynolds Tobacco Company | Smoking article with dual burn rate fuel element |
US4917120A (en) | 1986-05-21 | 1990-04-17 | Advanced Tobacco Products, Inc. | Nicotine impact modification |
US4735217A (en) * | 1986-08-21 | 1988-04-05 | The Procter & Gamble Company | Dosing device to provide vaporized medicament to the lungs as a fine aerosol |
US4858630A (en) | 1986-12-08 | 1989-08-22 | R. J. Reynolds Tobacco Company | Smoking article with improved aerosol forming substrate |
US4734560A (en) | 1987-01-20 | 1988-03-29 | Medical Enterprises, Ltd. | Vaporizing unit |
US4819665A (en) | 1987-01-23 | 1989-04-11 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US4924883A (en) * | 1987-03-06 | 1990-05-15 | R. J. Reynolds Tobacco Company | Smoking article |
US5017575A (en) | 1987-06-09 | 1991-05-21 | Golwyn Daniel H | Treatment of immunologically based disorders, specifically Crohn's disease |
GB8713645D0 (en) | 1987-06-11 | 1987-07-15 | Imp Tobacco Ltd | Smoking device |
US5019122A (en) | 1987-08-21 | 1991-05-28 | R. J. Reynolds Tobacco Company | Smoking article with an enclosed heat conductive capsule containing an aerosol forming substance |
US4906417A (en) | 1988-02-08 | 1990-03-06 | Associated Mills Inc. | Humidifier |
US4853517A (en) | 1988-03-28 | 1989-08-01 | John G. Bowen | Vaporizing unit |
US4906119A (en) * | 1988-04-14 | 1990-03-06 | Lloyd Hartford | Handwriting stabilizer |
DE3815221C2 (en) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli |
US4881556A (en) | 1988-06-06 | 1989-11-21 | R. J. Reynolds Tobacco Company | Low CO smoking article |
US5345951A (en) * | 1988-07-22 | 1994-09-13 | Philip Morris Incorporated | Smoking article |
US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
EP0358114A3 (en) | 1988-09-08 | 1990-11-14 | R.J. Reynolds Tobacco Company | Aerosol delivery articles utilizing electrical energy |
US4947875A (en) | 1988-09-08 | 1990-08-14 | R. J. Reynolds Tobacco Company | Flavor delivery articles utilizing electrical energy |
US4947874A (en) | 1988-09-08 | 1990-08-14 | R. J. Reynolds Tobacco Company | Smoking articles utilizing electrical energy |
USRE36744E (en) | 1988-09-16 | 2000-06-20 | Ribogene, Inc. | Nasal administration of benzodiazepine hypnotics |
US4950664A (en) | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
US4963289A (en) | 1988-09-19 | 1990-10-16 | The United States Of America As Represented By The United States Department Of Energy | Method for producing monodisperse aerosols |
US5511726A (en) | 1988-09-23 | 1996-04-30 | Battelle Memorial Institute | Nebulizer device |
US4917119A (en) | 1988-11-30 | 1990-04-17 | R. J. Reynolds Tobacco Company | Drug delivery article |
US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
GB8900267D0 (en) | 1989-01-06 | 1989-03-08 | Riker Laboratories Inc | Narcotic analgesic formulations and apparatus containing same |
DE3908161A1 (en) * | 1989-03-13 | 1990-09-27 | Bat Cigarettenfab Gmbh | Smokable article |
JP3062760B2 (en) * | 1989-03-14 | 2000-07-12 | コニカ株式会社 | Compound lens |
AU643435B2 (en) | 1989-04-28 | 1993-11-18 | Riker Laboratories, Inc. | Dry powder inhalation device |
HUT60631A (en) | 1989-05-05 | 1992-10-28 | North Sydney Area Health Serv | Process for producing pharmaceutical compositions suitable for increasing fertility |
DE58905398D1 (en) * | 1989-05-17 | 1993-09-30 | Leifeld Gmbh & Co | Process for manufacturing a pulley. |
US4941483A (en) | 1989-09-18 | 1990-07-17 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US6313176B1 (en) | 1989-10-17 | 2001-11-06 | Everett J. Ellinwood, Jr. | Dosing method of administering deprenyl via intraoral administration or inhalation administration |
US6048857A (en) | 1989-10-17 | 2000-04-11 | Ellinwood, Jr.; Everett H. | Dosing method of administering medicaments via inhalation administration |
US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5060671A (en) | 1989-12-01 | 1991-10-29 | Philip Morris Incorporated | Flavor generating article |
US5144962A (en) * | 1989-12-01 | 1992-09-08 | Philip Morris Incorporated | Flavor-delivery article |
US5224498A (en) | 1989-12-01 | 1993-07-06 | Philip Morris Incorporated | Electrically-powered heating element |
CA2070823C (en) | 1989-12-05 | 1999-01-12 | William H. Ii Frey | Neurologic agents for nasal administration to the brain |
GB2239807A (en) | 1990-01-09 | 1991-07-17 | Boc Group Plc | Anaesthetic vaporiser |
US5376386A (en) | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
US5099861A (en) | 1990-02-27 | 1992-03-31 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US5366770A (en) | 1990-04-17 | 1994-11-22 | Xingwu Wang | Aerosol-plasma deposition of films for electronic cells |
US5455043A (en) | 1990-06-13 | 1995-10-03 | Fischel-Ghodsian; Fariba | Device for controlled release of vaporous medications through nasal route |
US5126123A (en) | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
DE69110785T3 (en) * | 1990-08-02 | 2002-05-23 | Boc Group Plc | Anesthetic vaporizers. |
US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
US5166202A (en) | 1990-09-19 | 1992-11-24 | Trustees Of The University Of Pennsylvania | Method for the treatment of panic disorder |
US5175152A (en) | 1990-09-28 | 1992-12-29 | Singh Nikhilesh N | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form |
US5343226A (en) * | 1990-09-28 | 1994-08-30 | Dataproducts Corporation | Ink jet ink supply apparatus |
ATE179605T1 (en) | 1991-02-09 | 1999-05-15 | B S D Bio Science Dev Snc Di O | ANTIREACTIVE ANTIASTHMATIC EFFECT OF ACETYL SALICYLIC ACID BY INHALATION |
US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
US5457100A (en) | 1991-12-02 | 1995-10-10 | Daniel; David G. | Method for treatment of recurrent paroxysmal neuropsychiatric |
US5639441A (en) | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
US5626871A (en) | 1992-06-12 | 1997-05-06 | Teijin Limited | Preparation for intratracheobronchial administration |
US5622944A (en) | 1992-06-12 | 1997-04-22 | Affymax Technologies N.V. | Testosterone prodrugs for improved drug delivery |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US5284133A (en) * | 1992-07-23 | 1994-02-08 | Armstrong Pharmaceuticals, Inc. | Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means |
WO1994009842A1 (en) * | 1992-10-28 | 1994-05-11 | Rosen Charles A | Method and devices for delivering drugs by inhalation |
US5672581A (en) | 1993-01-29 | 1997-09-30 | Aradigm Corporation | Method of administration of insulin |
US5915378A (en) | 1993-01-29 | 1999-06-29 | Aradigm Corporation | Creating an aerosolized formulation of insulin |
US5724957A (en) | 1993-01-29 | 1998-03-10 | Aradigm Corporation | Intrapulmonary delivery of narcotics |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5507277A (en) | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
US5694919A (en) | 1993-01-29 | 1997-12-09 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activated dispenser |
US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
US5357257A (en) * | 1993-04-05 | 1994-10-18 | General Electric Company | Apparatus and method for equalizing channels in a multi-channel communication system |
US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
US5666977A (en) * | 1993-06-10 | 1997-09-16 | Philip Morris Incorporated | Electrical smoking article using liquid tobacco flavor medium delivery system |
US5894841A (en) | 1993-06-29 | 1999-04-20 | Ponwell Enterprises Limited | Dispenser |
US5388574A (en) | 1993-07-29 | 1995-02-14 | Ingebrethsen; Bradley J. | Aerosol delivery article |
DE4328243C1 (en) | 1993-08-19 | 1995-03-09 | Sven Mielordt | Smoke or inhalation device |
US5456247A (en) | 1993-08-26 | 1995-10-10 | Iowa State University Research Foundation, Inc. | Method for delivering drugs soluble in a vaporization vehicle |
FI98270C (en) | 1993-11-29 | 1997-05-26 | Instrumentarium Oy | Method and apparatus for evaporation of anesthetic agent |
US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
US5451408A (en) | 1994-03-23 | 1995-09-19 | Liposome Pain Management, Ltd. | Pain management with liposome-encapsulated analgesic drugs |
US6102036A (en) | 1994-04-12 | 2000-08-15 | Smoke-Stop | Breath activated inhaler |
JP3911290B2 (en) | 1994-05-13 | 2007-05-09 | アラダイム コーポレーション | Anesthesia prescription with aerosol |
US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
EP0785788B1 (en) | 1994-10-14 | 2001-12-12 | GLAXO WELLCOME S.p.A. | Use of cck-b receptor antagonists for the treatment of sleep disorders |
AU709572B2 (en) | 1994-10-28 | 1999-09-02 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5767117A (en) | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
CA2216443A1 (en) | 1995-03-31 | 1996-10-03 | Aradigm Corporation | Intrapulmonary delivery of hematopoietic drug |
US5758637A (en) | 1995-08-31 | 1998-06-02 | Aerogen, Inc. | Liquid dispensing apparatus and methods |
US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
DE19519056A1 (en) | 1995-05-24 | 1997-01-16 | Klinge Co Chem Pharm Fab | Use of antidepressants for the treatment of asthma and / or respiratory diseases by inhalation |
US5874481A (en) * | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
US6245347B1 (en) * | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
JPH0943487A (en) | 1995-08-01 | 1997-02-14 | Fuji Photo Film Co Ltd | Zoom lens |
US5649554A (en) * | 1995-10-16 | 1997-07-22 | Philip Morris Incorporated | Electrical lighter with a rotatable tobacco supply |
AU7669496A (en) | 1995-11-03 | 1997-05-22 | University Of Kentucky | Method for the intranasal administration of l-dopa prodrugs |
US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
US5564442A (en) * | 1995-11-22 | 1996-10-15 | Angus Collingwood MacDonald | Battery powered nicotine vaporizer |
US6041777A (en) * | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
ATE263546T1 (en) | 1995-12-14 | 2004-04-15 | Taisho Pharmaceutical Co Ltd | AEROSOL PREPARATION |
SE9504580L (en) * | 1995-12-21 | 1997-06-22 | Siemens Elema Ab | Procedure for gasification of an anesthetic fluid and a carburetor |
WO1997027804A1 (en) | 1996-02-05 | 1997-08-07 | Aradigm Corporation | Ventilation imaging using a fine particle aerosol generator |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5927124A (en) * | 1996-03-05 | 1999-07-27 | Adaptive Motion Control Systems, Inc. | Apparatus for bending and cutting tubing, and method of using same |
GB9606188D0 (en) | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
GB9606677D0 (en) | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
EP0896525B1 (en) * | 1996-04-29 | 2003-08-27 | Dura Pharmaceuticals, Inc. | Methods of dry powder inhalation |
US5743251A (en) | 1996-05-15 | 1998-04-28 | Philip Morris Incorporated | Aerosol and a method and apparatus for generating an aerosol |
US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
GB9613015D0 (en) | 1996-06-21 | 1996-08-28 | Reckitt & Colman Inc | Device |
JP2001508027A (en) | 1996-07-11 | 2001-06-19 | ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ | Pharmaceutical composition containing acid addition salt of basic drug |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US6694975B2 (en) * | 1996-11-21 | 2004-02-24 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US5906202A (en) | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
PT954282E (en) | 1997-01-16 | 2005-06-30 | Massachusetts Inst Technology | PREPARATION OF PARTICLES FOR INHALATION |
WO1998034595A1 (en) | 1997-02-05 | 1998-08-13 | Jago Research Ag | Medical aerosol formulations |
US5829435A (en) | 1997-02-24 | 1998-11-03 | Aradigm Corporation | Prefilter for prevention of clogging of a nozzle in the generation of an aerosol and prevention of administration of undesirable particles |
US5837713A (en) | 1997-02-26 | 1998-11-17 | Mayo Foundation For Medical Education And Research | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids |
KR100289448B1 (en) | 1997-07-23 | 2001-05-02 | 미즈노 마사루 | Flavor generator |
US5874841A (en) * | 1997-07-28 | 1999-02-23 | Philips Electronics North America Corporation | Sample-and-hold circuit for a switched-mode power supply |
US6090212A (en) * | 1997-08-15 | 2000-07-18 | Micro C Technologies, Inc. | Substrate platform for a semiconductor substrate during rapid high temperature processing and method of supporting a substrate |
EP1019021B2 (en) | 1997-09-29 | 2012-12-26 | Novartis AG | Stabilized preparations for use in metered dose inhalers |
US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US5915841A (en) * | 1998-01-05 | 1999-06-29 | Capstone Turbine Corporation | Compliant foil fluid film radial bearing |
US20020006181A1 (en) | 1998-01-23 | 2002-01-17 | Mackenzie Innes K. | Method and device for estimating bone mineral content of the calcaneus |
US6158431A (en) | 1998-02-13 | 2000-12-12 | Tsi Incorporated | Portable systems and methods for delivery of therapeutic material to the pulmonary system |
US6544542B1 (en) | 1998-03-05 | 2003-04-08 | Nippon Shinyaku Co., Ltd. | Fat emulsions for inhalational administration |
US6228875B1 (en) * | 1998-04-14 | 2001-05-08 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
AU4680699A (en) | 1998-06-12 | 1999-12-30 | Aradigm Corporation | Methods of delivering aerosolized polynucleotides to the respiratory tract |
US6095153A (en) | 1998-06-19 | 2000-08-01 | Kessler; Stephen B. | Vaporization of volatile materials |
TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
WO2000000215A1 (en) | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
MA25590A1 (en) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | ACTIVE AGENT FOR DRY POWDER DELIVERY |
US6234167B1 (en) | 1998-10-14 | 2001-05-22 | Chrysalis Technologies, Incorporated | Aerosol generator and methods of making and using an aerosol generator |
US6509005B1 (en) | 1998-10-27 | 2003-01-21 | Virginia Commonwealth University | Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler |
US6255334B1 (en) * | 1998-10-30 | 2001-07-03 | Pfizer Inc | 5HT 1 receptor agonists and metoclopramide for the treatment of migraine |
ATE353630T1 (en) | 1998-11-12 | 2007-03-15 | Transave Inc | INHALATION SYSTEM |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
EP1283036B2 (en) | 1998-11-13 | 2020-01-01 | Jagotec AG | Dry powder for inhalation |
US6070575A (en) | 1998-11-16 | 2000-06-06 | Aradigm Corporation | Aerosol-forming porous membrane with certain pore structure |
IL143576A0 (en) | 1998-12-11 | 2002-04-21 | Pharmachemie Bv | Pharmaceutical preparation for inhalation of an opioid |
US6376550B1 (en) | 1999-02-09 | 2002-04-23 | Asta Medica Ag | Pharmaceutical compositions containing tramadol for migraine |
AU2879100A (en) | 1999-02-12 | 2000-08-29 | Miles A. Libbey Iii | Formulation and system for intra-oral delivery of pharmaceutical agents |
US6591839B2 (en) * | 1999-02-17 | 2003-07-15 | Dieter Meyer | Filter material for reducing harmful substances in tobacco smoke |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
JP2002543092A (en) | 1999-04-27 | 2002-12-17 | イーライ・リリー・アンド・カンパニー | Insulin crystals for pulmonary administration |
AU4979700A (en) | 1999-05-03 | 2000-11-17 | Battelle Memorial Institute | Compositions for aerosolization and inhalation |
US6428769B1 (en) | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
GB9912356D0 (en) * | 1999-05-26 | 1999-07-28 | Btg Int Ltd | Generation of microfoam |
CN1240373C (en) | 1999-05-27 | 2006-02-08 | 阿库斯菲尔公司 | Porous drug matrices and methods of manufacture thereof |
AU767486B2 (en) | 1999-06-11 | 2003-11-13 | Aradigm Corporation | Method for producing an aerosol |
US20020061281A1 (en) | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
CA2378913C (en) | 1999-07-16 | 2010-02-23 | Aradigm Corporation | System for effecting smoke cessation |
BR0013122A (en) * | 1999-08-13 | 2002-04-30 | Vela Pharmaceuticals Inc | Cyclobenzaprine for treatment of generalized anxiety disorder and cyclobenzaprine compositions |
EP1210121A2 (en) | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
WO2001017568A2 (en) | 1999-09-07 | 2001-03-15 | Conjuchem, Inc. | Bioconjugation in vivo to pulmonary or blood components |
DE60026155T2 (en) | 1999-09-30 | 2006-08-10 | Neurogen Corp., Branford | SOME ALKYLENDIAMINE-SUBSTITUTED HETEROCYCLES |
EP1169924A4 (en) * | 1999-10-19 | 2002-05-15 | Agromedic Co Ltd | Method of feeding reproductive female pigs and feeds for reproductive female pigs |
DK1223915T3 (en) | 1999-10-29 | 2006-03-06 | Nektar Therapeutics | Dry powder preparations with improved dispersivity |
AU1261501A (en) | 1999-12-06 | 2001-06-18 | Stanley L. Gore | Compositions and methods for intranasal delivery of active agents to the brain |
US6853310B2 (en) * | 1999-12-29 | 2005-02-08 | Ge Medical Systems Information Technologies, Inc. | Tri-mode medical telemetry antenna system |
EP1941868A3 (en) * | 2000-02-28 | 2011-06-29 | PharmaKodex Limited | Improvements in or relating to the delivery of oral drugs |
JP2003532640A (en) * | 2000-04-07 | 2003-11-05 | タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド | Apomorphine derivative and method of using the same |
US6632047B2 (en) * | 2000-04-14 | 2003-10-14 | Board Of Regents, The University Of Texas System | Heater element for use in an in situ thermal desorption soil remediation system |
MY136453A (en) * | 2000-04-27 | 2008-10-31 | Philip Morris Usa Inc | "improved method and apparatus for generating an aerosol" |
WO2001093846A2 (en) | 2000-05-23 | 2001-12-13 | The Trustees Of Columbia University In The City Of New York | Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
AU2001225663A1 (en) | 2000-06-15 | 2001-12-24 | Respiratorius Ab | A composition comprising a combination of receptor agonists and antagonists |
GB0015981D0 (en) | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
FR2812545B1 (en) | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | INHALABLE DRUG AEROSOL FOR TREATMENT OR PREVENTION OF SWEETNESS |
US6514482B1 (en) | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US20020117175A1 (en) * | 2000-10-27 | 2002-08-29 | Kottayil S. George | Thermal vaporizing device for drug delivery |
EP1383376A4 (en) * | 2001-03-19 | 2006-03-08 | Praecis Pharm Inc | Pharmaceutical formulations for sustained release |
US20030004142A1 (en) * | 2001-04-18 | 2003-01-02 | Prior Christopher P. | Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway |
JP4357842B2 (en) * | 2001-05-24 | 2009-11-04 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Delivery of alprazolam, estazolam, midazolam or triazolam by a prescribed inhalation route |
US7498019B2 (en) * | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
US20030118512A1 (en) * | 2001-10-30 | 2003-06-26 | Shen William W. | Volatilization of a drug from an inclusion complex |
US7458374B2 (en) * | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US20030051728A1 (en) * | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
EP1392262A1 (en) * | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US7090830B2 (en) * | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US20080038363A1 (en) * | 2001-05-24 | 2008-02-14 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
US20030131843A1 (en) * | 2001-11-21 | 2003-07-17 | Lu Amy T. | Open-celled substrates for drug delivery |
US20030032638A1 (en) | 2001-05-24 | 2003-02-13 | Kim John J. | Delivery of benzodiazepines through an inhalation route |
US20070122353A1 (en) * | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US7645442B2 (en) * | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US20030138508A1 (en) * | 2001-12-18 | 2003-07-24 | Novack Gary D. | Method for administering an analgesic |
US7585493B2 (en) * | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
WO2002094242A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan or zolmitriptan through an inhalation route |
WO2003041693A1 (en) * | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
AU2002363947A1 (en) * | 2001-11-21 | 2003-07-24 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
US6701922B2 (en) * | 2001-12-20 | 2004-03-09 | Chrysalis Technologies Incorporated | Mouthpiece entrainment airflow control for aerosol generators |
US6772756B2 (en) * | 2002-02-09 | 2004-08-10 | Advanced Inhalation Revolutions Inc. | Method and system for vaporization of a substance |
WO2003094900A1 (en) * | 2002-05-13 | 2003-11-20 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
US20060193788A1 (en) * | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
US7074806B2 (en) * | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7485143B2 (en) * | 2002-11-15 | 2009-02-03 | Abbott Cardiovascular Systems Inc. | Apparatuses and methods for heart valve repair |
KR100459905B1 (en) * | 2002-11-21 | 2004-12-03 | 삼성전자주식회사 | Monolithic inkjet printhead having heater disposed between dual ink chamber and method of manufacturing thereof |
US20040105818A1 (en) * | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
DK1567164T3 (en) * | 2002-11-26 | 2009-05-18 | Alexza Pharmaceuticals Inc | Use of loxapine in the manufacture of a medicament for the treatment of pain |
US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
JP2006514633A (en) | 2002-11-26 | 2006-05-11 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Treatment of headache with antipsychotics delivered by inhalation |
US7913688B2 (en) * | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
EP1625336B9 (en) * | 2003-05-21 | 2012-03-21 | Alexza Pharmaceuticals, Inc. | Use of a layer of solid fuel, method for producing such a layer and associated heating unit |
US20050037506A1 (en) * | 2003-08-04 | 2005-02-17 | Alexza Molecular Delivery Corporation | Methods of determining film thicknesses for an aerosol delivery article |
EP1656171B9 (en) * | 2003-08-04 | 2010-10-20 | Alexza Pharmaceuticals, Inc. | Substrates for drug delivery device and methods of preparing |
CA2551127A1 (en) * | 2003-12-15 | 2005-07-07 | Alexza Pharmaceuticals, Inc. | Treatment of breakthrough pain by drug aerosol inhalation |
US20050131739A1 (en) * | 2003-12-16 | 2005-06-16 | Alexza Molecular Delivery Corporation | Methods for monitoring severity of panic attacks and other rapidly evolving medical events in real time |
US7402777B2 (en) * | 2004-05-20 | 2008-07-22 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
US7540286B2 (en) * | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
WO2006022714A1 (en) * | 2004-08-12 | 2006-03-02 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
US20060032496A1 (en) * | 2004-08-12 | 2006-02-16 | Alexza Molecular Delivery Corporation | Inhalation actuated percussive ignition system |
US20060120962A1 (en) * | 2004-10-12 | 2006-06-08 | Rabinowitz Joshua D | Cardiac safe, rapid medication delivery |
US7524848B2 (en) * | 2006-03-23 | 2009-04-28 | Amgen Inc. | Diaza heterocyclic amide compounds and their uses |
WO2008080170A1 (en) | 2006-12-22 | 2008-07-03 | Alexza Pharmaceuticals, Inc. | Mixed drug aerosol compositiions |
US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US20080306285A1 (en) | 2007-04-27 | 2008-12-11 | Alexza Pharmaceuticals, Inc. | Heat-Labile Prodrugs |
-
2002
- 2002-05-13 EP EP02741994A patent/EP1392262A1/en not_active Withdrawn
- 2002-05-13 JP JP2003530268A patent/JP2005503425A/en active Pending
- 2002-05-13 CA CA002446904A patent/CA2446904A1/en not_active Abandoned
- 2002-05-13 US US10/146,516 patent/US6737042B2/en not_active Expired - Fee Related
- 2002-05-15 AU AU2002314784A patent/AU2002314784A1/en not_active Abandoned
- 2002-05-15 US US10/150,268 patent/US6780399B2/en not_active Expired - Fee Related
- 2002-05-15 US US10/150,267 patent/US6797259B2/en not_active Expired - Fee Related
- 2002-05-16 US US10/151,596 patent/US6855310B2/en not_active Expired - Fee Related
- 2002-05-16 US US10/151,626 patent/US6783753B2/en not_active Expired - Lifetime
- 2002-05-16 EP EP02729255A patent/EP1389095A1/en not_active Withdrawn
- 2002-05-17 JP JP2002590949A patent/JP4578772B2/en not_active Expired - Fee Related
- 2002-05-17 DE DE60235851T patent/DE60235851D1/en not_active Expired - Lifetime
- 2002-05-17 CA CA002446990A patent/CA2446990C/en not_active Expired - Fee Related
- 2002-05-17 AT AT02771848T patent/ATE401064T1/en not_active IP Right Cessation
- 2002-05-17 US US10/150,857 patent/US6716415B2/en not_active Expired - Lifetime
- 2002-05-17 NZ NZ529422A patent/NZ529422A/en unknown
- 2002-05-17 EP EP02729235A patent/EP1389094B1/en not_active Expired - Lifetime
- 2002-05-17 EP EP02771848A patent/EP1392264B1/en not_active Expired - Lifetime
- 2002-05-17 US US10/150,591 patent/US6780400B2/en not_active Expired - Lifetime
- 2002-05-17 ES ES02729235T patent/ES2312571T3/en not_active Expired - Lifetime
- 2002-05-17 EP EP08014271A patent/EP1987823B1/en not_active Expired - Lifetime
- 2002-05-17 AT AT08014271T patent/ATE462420T1/en not_active IP Right Cessation
- 2002-05-17 ES ES08014271T patent/ES2341594T3/en not_active Expired - Lifetime
- 2002-05-17 AT AT02729235T patent/ATE406878T1/en active
- 2002-05-20 DE DE60235852T patent/DE60235852D1/en not_active Expired - Lifetime
- 2002-05-20 ES ES02737053T patent/ES2311607T3/en not_active Expired - Lifetime
- 2002-05-20 EP EP08014272A patent/EP1990046B1/en not_active Expired - Lifetime
- 2002-05-20 US US10/153,139 patent/US6814954B2/en not_active Expired - Lifetime
- 2002-05-20 AT AT08014272T patent/ATE462421T1/en not_active IP Right Cessation
- 2002-05-20 DE DE60228232T patent/DE60228232D1/en not_active Expired - Lifetime
- 2002-05-20 AU AU2002310015A patent/AU2002310015B2/en not_active Expired
- 2002-05-20 EP EP02737053A patent/EP1389098B1/en not_active Expired - Lifetime
- 2002-05-20 DK DK02737053T patent/DK1389098T3/en active
- 2002-05-20 JP JP2002590955A patent/JP4578773B2/en not_active Expired - Lifetime
- 2002-05-20 US US10/152,652 patent/US6740307B2/en not_active Expired - Fee Related
- 2002-05-20 NZ NZ529419A patent/NZ529419A/en unknown
- 2002-05-20 WO PCT/US2002/016118 patent/WO2002094236A1/en active Application Filing
- 2002-05-20 EP EP02731896A patent/EP1389097B1/en not_active Expired - Lifetime
- 2002-05-20 PL PL02363996A patent/PL363996A1/en unknown
- 2002-05-20 US US10/152,640 patent/US6743415B2/en not_active Expired - Fee Related
- 2002-05-20 PT PT02737053T patent/PT1389098E/en unknown
- 2002-05-20 AT AT02737053T patent/ATE404173T1/en active
- 2002-05-20 CA CA002446917A patent/CA2446917C/en not_active Expired - Lifetime
- 2002-05-20 AT AT02731896T patent/ATE404184T1/en not_active IP Right Cessation
- 2002-05-20 EP EP02737054A patent/EP1389099A1/en not_active Withdrawn
- 2002-05-20 MX MXPA03010703A patent/MXPA03010703A/en active IP Right Grant
- 2002-05-20 ES ES08014272T patent/ES2341392T3/en not_active Expired - Lifetime
- 2002-05-20 US US10/152,639 patent/US6716416B2/en not_active Expired - Lifetime
- 2002-05-21 NZ NZ529420A patent/NZ529420A/en unknown
- 2002-05-21 US US10/153,839 patent/US6776978B2/en not_active Expired - Lifetime
- 2002-05-21 CA CA002446916A patent/CA2446916C/en not_active Expired - Fee Related
- 2002-05-21 PT PT02731894T patent/PT1389096E/en unknown
- 2002-05-21 EP EP02731930A patent/EP1392257B1/en not_active Expired - Lifetime
- 2002-05-21 JP JP2002590964A patent/JP2004535403A/en active Pending
- 2002-05-21 EP EP02731894A patent/EP1389096B9/en not_active Expired - Lifetime
- 2002-05-21 AT AT02731930T patent/ATE401063T1/en not_active IP Right Cessation
- 2002-05-21 US US10/153,831 patent/US6740308B2/en not_active Expired - Lifetime
- 2002-05-21 CA CA002447521A patent/CA2447521C/en not_active Expired - Fee Related
- 2002-05-21 US US10/153,311 patent/US6884408B2/en not_active Expired - Fee Related
- 2002-05-21 AU AU2002303833A patent/AU2002303833B2/en not_active Ceased
- 2002-05-21 ES ES02731894T patent/ES2324023T3/en not_active Expired - Lifetime
- 2002-05-21 AT AT02731894T patent/ATE425746T1/en active
- 2002-05-21 NZ NZ529421A patent/NZ529421A/en unknown
- 2002-05-22 CA CA002447166A patent/CA2447166C/en not_active Expired - Fee Related
- 2002-05-22 PL PL02363997A patent/PL363997A1/en not_active Application Discontinuation
- 2002-05-22 US US10/155,703 patent/US6803031B2/en not_active Expired - Fee Related
- 2002-05-22 US US10/155,705 patent/US6805854B2/en not_active Expired - Fee Related
- 2002-05-22 AT AT02737132T patent/ATE365548T1/en not_active IP Right Cessation
- 2002-05-22 DE DE60220909T patent/DE60220909T2/en not_active Expired - Lifetime
- 2002-05-22 EP EP02737132A patent/EP1392259B1/en not_active Expired - Lifetime
- 2002-05-22 NZ NZ529418A patent/NZ529418A/en unknown
- 2002-05-22 JP JP2002590938A patent/JP2004531556A/en active Pending
- 2002-05-23 US US10/154,594 patent/US6740309B2/en not_active Expired - Fee Related
- 2002-05-23 MX MXPA03010702A patent/MXPA03010702A/en active IP Right Grant
- 2002-05-23 CA CA2447099A patent/CA2447099C/en not_active Expired - Fee Related
- 2002-05-23 EP EP02739410A patent/EP1392261B1/en not_active Expired - Lifetime
- 2002-05-23 AT AT02737120T patent/ATE418330T1/en not_active IP Right Cessation
- 2002-05-23 EP EP02737120A patent/EP1390021B1/en not_active Expired - Lifetime
- 2002-05-23 US US10/154,765 patent/US6814955B2/en not_active Expired - Fee Related
- 2002-05-23 PL PL02364002A patent/PL364002A1/en unknown
- 2002-05-23 NZ NZ529416A patent/NZ529416A/en unknown
- 2002-05-23 US US10/155,097 patent/US6716417B2/en not_active Expired - Fee Related
- 2002-05-23 AT AT02739410T patent/ATE418971T1/en not_active IP Right Cessation
- 2002-05-23 JP JP2002590960A patent/JP2004532860A/en active Pending
-
2003
- 2003-12-12 US US10/735,199 patent/US7070761B2/en not_active Expired - Fee Related
- 2003-12-12 US US10/734,902 patent/US7029658B2/en not_active Expired - Fee Related
- 2003-12-12 US US10/735,496 patent/US7005121B2/en not_active Expired - Fee Related
- 2003-12-12 US US10/735,198 patent/US7008615B2/en not_active Expired - Fee Related
- 2003-12-12 US US10/735,497 patent/US7070762B2/en not_active Expired - Fee Related
- 2003-12-30 US US10/749,535 patent/US7115250B2/en not_active Expired - Fee Related
- 2003-12-30 US US10/749,537 patent/US7078017B2/en not_active Expired - Lifetime
- 2003-12-30 US US10/749,783 patent/US7078019B2/en not_active Expired - Fee Related
- 2003-12-30 US US10/749,536 patent/US7094392B2/en not_active Expired - Fee Related
- 2003-12-30 US US10/749,539 patent/US7078018B2/en not_active Expired - Lifetime
- 2003-12-30 US US10/750,303 patent/US7078020B2/en not_active Expired - Lifetime
-
2004
- 2004-01-27 US US10/766,647 patent/US7070764B2/en not_active Expired - Fee Related
- 2004-01-27 US US10/766,149 patent/US7087216B2/en not_active Expired - Lifetime
- 2004-01-27 US US10/766,279 patent/US7087217B2/en not_active Expired - Fee Related
- 2004-01-27 US US10/766,566 patent/US7060254B2/en not_active Expired - Fee Related
- 2004-01-27 US US10/766,574 patent/US7045118B2/en not_active Expired - Lifetime
- 2004-01-27 US US10/766,634 patent/US7070763B2/en not_active Expired - Lifetime
- 2004-01-28 US US10/767,115 patent/US7052679B2/en not_active Expired - Lifetime
- 2004-01-29 US US10/769,197 patent/US7063831B2/en not_active Expired - Fee Related
- 2004-01-29 US US10/768,205 patent/US7070765B2/en not_active Expired - Lifetime
- 2004-01-29 US US10/768,281 patent/US7169378B2/en not_active Expired - Lifetime
- 2004-01-29 US US10/768,293 patent/US7067114B2/en not_active Expired - Fee Related
- 2004-01-29 US US10/768,220 patent/US7063830B2/en not_active Expired - Fee Related
- 2004-01-30 US US10/769,051 patent/US7033575B2/en not_active Expired - Fee Related
- 2004-01-30 US US10/769,046 patent/US7070766B2/en not_active Expired - Fee Related
- 2004-02-09 US US10/775,586 patent/US7048909B2/en not_active Expired - Fee Related
- 2004-02-09 US US10/775,583 patent/US7018620B2/en not_active Expired - Fee Related
- 2004-03-03 US US10/792,239 patent/US7014840B2/en not_active Expired - Fee Related
- 2004-03-03 US US10/791,915 patent/US7005122B2/en not_active Expired - Fee Related
- 2004-03-31 US US10/814,998 patent/US7108847B2/en not_active Expired - Fee Related
- 2004-03-31 US US10/814,690 patent/US7014841B2/en not_active Expired - Lifetime
- 2004-03-31 US US10/813,722 patent/US7063832B2/en not_active Expired - Fee Related
- 2004-03-31 US US10/813,721 patent/US7022312B2/en not_active Expired - Lifetime
- 2004-04-01 US US10/816,407 patent/US7011820B2/en not_active Expired - Fee Related
- 2004-04-01 US US10/816,567 patent/US7052680B2/en not_active Expired - Fee Related
- 2004-04-01 US US10/816,492 patent/US7008616B2/en not_active Expired - Fee Related
- 2004-04-01 US US10/815,527 patent/US6994843B2/en not_active Expired - Fee Related
-
2006
- 2006-03-07 US US11/370,628 patent/US7442368B2/en not_active Expired - Fee Related
- 2006-04-04 US US11/398,383 patent/US7449172B2/en not_active Expired - Lifetime
- 2006-05-24 US US11/439,475 patent/US7465435B2/en not_active Expired - Fee Related
- 2006-05-30 US US11/442,917 patent/US7465436B2/en not_active Expired - Fee Related
- 2006-06-13 US US11/451,853 patent/US7485285B2/en not_active Expired - Fee Related
- 2006-06-16 US US11/454,573 patent/US7465437B2/en not_active Expired - Fee Related
- 2006-06-30 US US11/479,892 patent/US7449174B2/en not_active Expired - Fee Related
- 2006-06-30 US US11/479,509 patent/US7507398B2/en not_active Expired - Fee Related
- 2006-06-30 US US11/479,361 patent/US7524484B2/en not_active Expired - Fee Related
- 2006-07-05 US US11/481,279 patent/US7449175B2/en not_active Expired - Fee Related
- 2006-07-18 US US11/488,943 patent/US20060257329A1/en not_active Abandoned
- 2006-07-18 US US11/488,932 patent/US7601337B2/en not_active Expired - Lifetime
- 2006-08-07 US US11/501,246 patent/US7510702B2/en not_active Expired - Fee Related
- 2006-08-07 US US11/500,735 patent/US7445768B2/en not_active Expired - Fee Related
- 2006-08-22 US US11/507,986 patent/US7491047B2/en not_active Expired - Fee Related
- 2006-09-19 US US11/523,685 patent/US7507397B2/en not_active Expired - Fee Related
-
2007
- 2007-01-09 US US11/621,397 patent/US7468179B2/en not_active Expired - Fee Related
-
2008
- 2008-03-27 US US12/057,330 patent/US7988952B2/en not_active Expired - Fee Related
-
2009
- 2009-03-27 US US12/413,339 patent/US8173107B2/en not_active Expired - Lifetime
-
2010
- 2010-07-23 JP JP2010165688A patent/JP5629151B2/en not_active Expired - Lifetime
-
2013
- 2013-08-19 BE BE2013C054C patent/BE2013C054I2/nl unknown
- 2013-08-19 FR FR13C0051C patent/FR13C0051I1/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7169378B2 (en) | Delivery of opioids through an inhalation route | |
AU2002303833A1 (en) | Delivery of opioids through an inhalation route | |
WO2002094234A1 (en) | Delivery of opioids through an inhalation route | |
WO2002094233A1 (en) | Delivery of antiemetics through an inhalation route | |
AU2008200911B2 (en) | Delivery of opioids through an inhalation route | |
WO2002094216A2 (en) | Delivery of stimulants through an inhalation route | |
WO2002094231A1 (en) | Delivery of analgesics through an inhalation route | |
WO2002094229A1 (en) | Delivery of muscle relaxants through an inhalation route | |
WO2002094235A1 (en) | Delivery of compounds for the treatment of parkinsons through an inhalation route | |
WO2002094240A1 (en) | Delivery of physiologically active compounds through an inhalation route | |
WO2002094239A1 (en) | Delivery of diphenhydramine through an inhalation route |